CA2181377C

CA2181377C - Tetracyclic derivatives, process of preparation and use

Info

Publication number: CA2181377C
Application number: CA002181377A
Authority: CA
Inventors: Alain Claude-Marie Daugan
Original assignee: Icos Corp
Current assignee: Icos Corp
Priority date: 1994-01-21
Filing date: 1995-01-19
Publication date: 2002-05-28
Anticipated expiration: 2015-01-19
Also published as: EP0740668A1; NO963015L; NO963015D0; MA23433A1; AP556A; PL315559A1; NZ279199A; FI962927A0; SK94096A3; BG100727A; GB9401090D0; AU7391298A; CN1045777C; UY23893A1; DE10399006I2; JP3808095B2; NL300124I1; MX9602904A; HRP950023B1; DE69503753T2

Abstract

A compound of formula (I) and salts and solvates thereof, in which: R0 represents hydrogen, halogen or C1-6 alkyl; R1 represents hydrogen, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl; R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring (a) attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring (A) is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders.

Description

O W095/19978 ~ ~L 8 ~ 3 ~ 7 ~ 83 TETRACYCLIC DERIVATIVE'S. PROCE~S OF PP~EPARATION AND USE
This invention relates to a series of tetracyclic derivatives, to ~uuesses for their Ul~,UdldLiUII, ,ul,d""aceutical Culll,uuailiulla cu"k.i"i"5~ them, and their use as therapeutic agents. In particular, the invention relates to tetracyclic derivatives which are potent ar~d selective inhibitors of cyclic guanosine 3',5'-ullc~JIIua,ul1dLt: specific ~IIC~ ' dae (cGMP specific PDE) having utility in a variety of therapeutic al eas where such inhibition is thought to be beneficial, including the treatmellt of l,dl uiiu~as,,ular disorders.
1û Thus, according to a first as~)ect, the present invention provides compounds of formula (I) R~p R~
and salts and solvates (e.g. hydl ates) thereof, in which:
R I~ a~ a hydrogen, halc~gen or C1 6 alkyl;
15 R1 le:,ulc:aelllta hydrogen, C1.. 6alkyl, C2~alkenyl, C2~ alkynyl, haloC1 6alkyl, C3 gcycloalkyl, C3 gcycloalkylC1 3alkyl, arylC1 3alkyl or heteroarylC1 3alkyl;
R2 I~ a~ la an optionally Cllh5titll ' monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally s~ ' bicyclic ring ~ attached to tlle rest of the molecule via one of the benzene 2û ring carbon atoms and whereirl the fused ring A is a 5- or 6-lllc:lllL~ d ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two I ,~ , u ~" ,:, selected from oxygen, sulphur and nitrogen; and R3 I~ hydrogen or C1.3 alkyl, or R1 and R3 together represent a 3- or 4- I,,~,,lL,t:lt:d alkyl or alkenyl chain.
There is further provided by the present invention a subgroup of compounds of formula (I), the subgroup ~IIIIp~ compounds of fommula (la) wo95/19978 r~ 7~.. 'C~1&3 ~'~
and salts and solvates (e.g. hydrates) thereof, in v,~hich:
R, C7,UI ~el ,t~ hydro3en, halogen or C1 -6 alkyl;
R1 Itl,ult~S~ a hydrogen, C1~alkyl, haloC1 6alkyl, C3~c~. ".yl, C3 gcycloalkylC1 3alkyl, arylC1 3alkyl or heteroarylC1 3alkyl; and R2 I~:,u,~ ts an optionaily s~hs~ t~d Illuilocy~ . aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally s~ ' bicyclic [~
ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-lll~",b~l~ i ring v"hich may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two h_:~.u~lll~ selected from oxygen, sulphur and nitrogen.
Within R1 above, the term "aryl" as part of an arylC1 3alkyl group means phenyl or phenyl s~h~t;t ~ :1 by one or more (e.g. 1, 2 or 3) substituents selected from halogen, C1 6alkyl, C1 6alkoxy and methyl~n~iio~y. The term "heteroaryl" as part of a heteroarylC1 3alkyl group means thienyl, furyl or pyridyi each optionally s~ IhCtitl 1' ' by one or more (e.g. 1, 2 or 3) substituents selected from halogen, C1 6 alkyl and C1 6alkoxy. The temm "C3 gcycloalkyl" as a group or part of a C3~cy, ' lkylC1 3alkyl group means a monocyclic ring cu,,,~.,i:.i,,~
three to eight carbon atoms. Examples of suitable cycloalkyl rings include the C3 6cycloalkyl rings cyclopropyl, cyclobutyl, cyclopentyl and cy~lul ,aA~I.
Within R2 above, optional benzene ring substituents are selected from one or more (e.g. 1, 2 or 3) atoms or groups ~",,u,i~i"g halogen, hydroxy, C1 6alkyl, C1 6alkoxy, -CO2Rb, haloC1 6alkyl, haloC1 6alkoxy, cyano, nitro and NRaRb, where Ra and Rb are each hydrogen or C1 6alkyl, or Ra may also represent C2 7alkanoyl or C1~alkylsulphonyl. Optional substituents for the remaining ring systems are selected from one or more (e.g. 1, 2 or 3) atoms or groups CUIII~ ;II9 halogen, C1 6alkyl, C1 6alkoxy and arylC,.3alkyl as defined above.

O wo g~/l9978 2 1 8 1 ~ 7 7 ~ 6~

The bicyclic ring ~J may, for example, represent lld,ul,ll,alene, all~,'~,,u~ such as b~"~u,~d~ule, be"~ull,id~ul~, b~",;~o~
, quino~ine, inidole, b~ u~l ~iu~ ene or benzofuran or ~x~
Y (where n is arl integer 1 or 2 and X and Y may each represent CH2, 0, S or NH).
In the above d~r" ,i~io, la, the temm "alkyl" as a group or part of a group means a straight chain or, where available, a branched chain alkyl moiety. For example, it may represent a C1.4alkyl function as ~ st:"led by methyl, ethyl, n-propyl, i-propyl, n-butyl, s-but~JI and t-butyl. The temm 'alkenyl' as used harein includes straight-chained and branched alkenyl groups, such as vinyl and allyl groups. The temm 'alkynyl' as used herein includes straight-chained and branched alkynyl groups, suitablly acetylene. The temm "halogen" herein means a fluorine, chlorine, bromine or iodine atom. The tem~ "haloC1 ~alkyl" means an alkyl group as defmed above ""~ i"g one to six carbon atoms s~hct~ ~r! at one or more carbon atoms by one or more (e.g. 1, 2 or 3) halogen atoms.
Similarly, a haloC1~alkoxy grc)up is a haloC1~alkyl group as defined above linked to the R2 benzene ring ~ia an oxygen atom. Examples of haloC1~alkyl groups include trifluoromethyl and 2,2,2-trifluoroethyl. An example of a haloC1~alkoxy group is trifl~u,u,,,_;l,~xy. Thr~ ten~ "C2 7alkanoyl" means a C1 ~,: 'kyl~,d,~u,,yl group where the C1~alkyl portion is as defined above. An example of a suitable C2 7alkar1oyl group is the C2alkanoyl group acetyl.
It will be d~ .idl~d that wllen R is a halogen atom or a C1~alkyl group this substituent may be sited at any available position on the phenyl pontion ofthe ~u~au~ , ring. However, a particular site of dlldulllllt:llL is the ring 1û-position.
The compounds of formula l'l) may contain two or more as~"""~ . centres and thus cdn exist as end"~iull,t:,a or ~idalt:lc:o;~.",e,a. In particular, in fommula (I) above two ring chiral cenltres are denoted with asterisks. It is to be.
ulldtslatuOd that the invention includes both mixtures and separate individual isomers of the compounds of formula (I).
The r,ompounds of fommula (I) may also exist in tautomeric forms and the invention includes both mixture.~ and separate individual tautomers thereof.

2 1 ~ 1 ~ 7 7 P~ 7~ 183 The phd~ t~ y A~ læ salts of the compounds of formula (I) which contain a basic centre are acid addition salts formed with plldl,l~
le acids. Examples include the hy-lluullluli~e, IIJIIuLlullli~, sulphate or bisulphate, ,ullui,~JlldL~ or hydrogen ph~ , acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, ~ tl Idl ,æsulphonate,benzenesulphonate and p-toiuenesulphonate salts. Compounds of the formula (I) can also provide IJIldlll~ metal salts, in particular alkali metal salts, with bases. Examples include the sodium and potassium salts.
A particular y^roup of compounds of the invention are those compounds of 1 û formula (I) in which R is hydrogen or halogen (e.g. fluorine), especially hydrogen.
Another particular group of compounds of the invention are those compounds of formula (I) in which R1 r~ul_a~ ;. hydrogen, C14alkyl, haloC14alkyl"
C3~cycloalkyl, C3~cycloalkylmethyl, pyridylC1 3alkyl, furylC1 3alkyl or optionally sl Ih5titl ~t-d benzyl. Within this particular group of compounds, examples of C14alkyl groups are methyl, ethyl, n-propyl, i-propyl and n-butyl.
Examples of C3~,cy,' 'kyll,._;:,yl groups are cyclopropylmethyl and cy~lùl,~xy,",~ l. Examples of optionally 511' '' 1' i, benzyl groups include benzyl and halobenzyl (e.g. fluorobenzyl).
A further particular group of compounds of the invention are those compounds of formula (I) in which R2 I~,U~ "~:~ sn optionally sllhe~t~
benzene, thiophene, furan, pyridine or ~ Id~.ll Itl Id~ e ring or an optionally SllhStitl It-d bicyclic ring Y (where n is 1 or 2 and X and Y are each CH2 or O). Within this particular group of compounds, examples of ~:llhstit~l~^i benzene groups are benzene sl~hstit~ by one of halogen (e.g.
chlorine), hydroxy, C1 3alkyl (e.g. methyl, ethyl or i-propyl), C1 3alkoxy (e.g.methoxy or ethoxy), -CO2Rb, lldlulll~l ,yl (e.g. trifluoromethyl), hdlu~ l ,u,~y (e.g.
trifluu,u,,,t:tl,uAy), cyano, nitro or NRaRb where Ra and Rb are each hydrogen or methyl or Ra js acetyl; or benzene s~ by dihalo (e.g. dichloro) or by C1 3alkoxy (e.g. methoxy) and one of halogen (e.g. chlorine) and hydroxy. An example of a s~ thiophene ring is a halo (e.g. bromo) substituent thiophene ring.

2~ 8~L3~7 O W09~119978 ~ . P~l/~7'.'C 18~

A still further particular group of compounds of fonmula I are those wherein R3 ,t:~,lt,:,t:"l:, hydrogen or Rl and 17~3 together represent a 3-lllc:lllLJc:l~d alkyl chain.
A preferred group of compt~unds of ~he invention are the cis isomers of fommula (I), ~ t~, ILtld by form~lla (Ib) R~[~ ~L (Ib) H
and mixtures thereof with their cis optical elldl lLiu~ including racemic mixtures, and salts and solvates (e.g. hydrates) of these compounds in which R is hydrogen or halogen (e.g. fluorine), especially hydrogen and R', R and R3 are as defined previously.
The single isomers rt~ st,llLe:d by formula (Ib), i.e. the 6R, 12aR isomers, ar~ particularly preferred.
Within the above definitions R1 may preferably represent C14alkyl (e.g.
methyl, ethyl, i-propyl and l1-butyl), C3 6cycloalkyl (e.g. c~ pt-"t~l) or C3 6cycloalkylmethyl (e.g. cyclopropylmethyl).
R2 may preferably represent a s~hstit~tPd benzene ring such as benzene 5llhstitllt~od by C1 3alkoxy (e.g. methoxy) or by C1 3alkoxy (e.g. methoxy) and halo3en (e.g. chlorine), particularly 4-",c:tllu~r ll~ l or 3-chloro4-methoxyphenyl, or R2 may preft~rably represent 3,4-methylel~tj~iuAyphenyl.
It is to be rJ"~t-,~Luod that the present invention covers all d~Jlu~ h ~"~L~i~ IdLiol~s of particular and preferred groupings h~l .,i, IdLJU. _.
Panticular individual compounds of the invention include:
Cis-2,3,6,7, 12,1 2a-hexahydro-2-(4-pyridylmethyl)-6-~3,4-methylenedioAyphenyl)-pyrazin~[2', 1 ': 6, 1 ]pyrido[3,4-b]indole-1 ,4-dione;
Cis-2,3,6,7, 12,1 2a-hexahydro-6~2,3-dih~l ubt~ u[b]furan-5-yl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]inldole-1,4-dione;
Cis-2,3,6,7, 12,1 2a-hexahydro-6-(5-bromo-2-thienyl)-2-methyl-pyrazino[2',1':6,1 ]pyrido[3,4-b]ir~dole -1 ,4-dione;
Cis-2,3,6,7,12,12a-hexahydro-2-butyl~-(4-methylphenyl)-pyrazino[2', 1':6,1 ]pyrido[3,4-b]ir~dole -1 ,4-dione;
3û (6R, 1 2aR)-2,3,6,7, 12,1 2a-Hexahydro-2-isopropyl-6-(3,4-methylel~e-liùAyphenyl)-pyrazint~[2',1':6,1 ]pyrido[3,4-b]indole -1 ,4-dione;

W0 95/19978 2 1 8 1 3 7 7 F ~ .l r.~ - loJ ~

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cy-:lu,u~"l~l 6-(3,4-methyle~e iiux-yph~,,yl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
(6R, 1 2aR)-2,3,6,7, 12,1 2a-Hexahydro-2~y~ JI u~ " ,~;: Iyl-6-(4-" ,~ 1Oxy~ el Iyl)-pyrazino[2', 1':6,1 ]pyrido[3,4-b]indole -1 ,4-dione;
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(3-chloro-4-methoxyphenyl)-2-methyl-pyrazino[2', 1':6,1 ]pyrido[3,4-b]indole -1 ,4-dione;
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methyl~ iiùxyphenyl)-pyrazino[2', 1':6,1 ]pyrido[3,4-b]indole-1 ,4-dione;
(6R, 1 2aR)-2,3,6,7, 12,1 2a-Hexahydro-6-(3,4-methylu.-e iiùxyphenyl)-1û pyrazino[2', 1': 6,1] pyrido [3,4-b] indole-1,4-dione;
(5aR, 12R, 14aS)-1,2,3,5,6,11,12,14a-Octahydro-12-(3,4-methylenedioxyphenyl)-pyrrolo[1",2": 4',5']pyrazino[2', 1 ': 6,1 ]pyrido[3,4-b]indole-5-1 ,4-dione;
and physiul~yi~'!y ~cr~ l le salts and solvates (e.g. hydrates) thereof.
A specific compound of the invention is:
(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylc:ne~iiù~ "yl)-pyrazino[2', 1':6,1 ]pyrido[3,4-b]indole -1 ,4-dione;
and physiulc,_ "y ~rr,~ salts and solvates (e.g. hydrates) thereof.
It has been shown that compounds of the present invention are potent and selective inhibitors of cGMP specific PDE. Thus, compounds of formula (I) are of interest for use in therapy, .pe.,iri. 3''y for the treatment of a variety ofconditions where inhibition of cGMP specific PDE is thought to be beneficial.
As a consequence of the selective PDE V inhibition exhibited by compounds of the present invention, cGMP levels are elevated, which in turn can give rise to beneficial anti-platelet, anti-neutrophil, anti-v-~o~ , v~ y, natriuretic and diuretic activities as well as F ' llidLiul, of the effects of endothelium-derived relaxing factor (EDRF), nitrovdsuu;'.,'u,~, atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and endothelium- ic:l,el, ie"~ relaxing agents such as bradykinin, acetylul, ' ,e and 5-HT1. The compounds of fommula (I) therefore have utility in the treatment of a number of disorders, including stabie, unstable and variant (Prinzmetal) angina, hype,l~"sic,,~, pulmonary hype~Lel~siu", ,u"u,~ heart failure, renal failure, d~llc:luacleluai~, conditions of reduced blood vessel patency (e.g. post-percutaneous transluminal coronary al,yiulJld~ly), peripheral vascular disease, . 35 vascular disorders such as Raynaud's disease, illrl~lllllld~uly diseases, stroke, .

WO 9S119978 ~ . 183 bronchitis, chronic asthma, all~rgic asthma, allergic rhinitis, glaucoma and diseases ~ dln.,l~liaed by dis~rders of gut motility (e.s. irritable bowel syndrome).
It will be d~U,UI ~_ ' ' ' that l l~ 5 herein to treatment extend to prophylaxis as well as treatment l~f ealdbli~.l ,ed conditions.
It will also be dlJ~UI I ' ' that 'a compound of formula (I),' or a phys,;ol~_i~",/
âalt or solvate thereof can be ddlllil 1 ' e:d as the raw compound, or as a l,l~d""aue:utical cu,,,,uùsiliùn cc" ,:..;. ,;"~ either entity.
There is thus provided as a further aspect of the invention a compound of fonmula (I) for use in the treatme!nt of stable, unstable and variant (Prinzmetal) angina, hyp~ "sio,~, pulmonar~/ h~,perlension, chronic obstructive pulmonary disease, cu"y~ c heart failure, renal failure, ~ luacl~luaiS, conditions of reduced blood vessel patency, (e.g. post-PTCA), peripheral vascular disease, vascular disorders such as Raynaud's disease, i,llld"""d~u,y diseases, stroke, bronchitis, chronic asthma, all~rgic asthma, allergic rhinitis, glaucoma or diseases cl Idl nule~ ,ed by disorders of gut motility (e.g. IBS).
According to another aspect ~f the invention, there is provided the use of a compound of formula (I) for the manufacture of a ,,,c:diw,,,c,,,l for the treatment of stable, unstable and variant (Prinzmetal) angina, h~p~ llaiull, pulmonary h~/,uc~ llaiull, chronic obstructive pulmonary disease, congestive heart failure, renal failure, dlll~lus~ luaia, col~ditions of reduced blood vessel patency, (e.g.
post-PTCA), peripheral vascular disease, vascular disorders such as Raynaud's disease, illllmllllldluly diseases, stroke, bronchitis, chronic asthma, allergicasthma, allergic rhinitis, glaucoma or diseases ,l IdldUL I iaed by disorders of gut motility (e.g. IBS).
In a further aspect, the invention provides a method of treating stable, unstable and variant (F~i".~",e:~al) angina, hyp~ sion, puimonary hy~ llaiull, chronic obstructiv~ pulmonary disease, congestive heart failure, renal failure, ~ l~luacl~luaia, uulluitions of reduced blood vessel patency, (e.g.
post-PTCA), peripheral vascular disease, vascular disorders such as Raynaud's disease, i"nd"", y diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma or diseases ul Idl nul~ lC~ by disorders of gut motility (e.g. IBS) in a human or non-human animal body which comprises ad~"i" i"g to said body a theMre~' 'Iy effective amount of a compound 35 with formula (I).
-WO 95/19978 2~ 1 8 1 3 7 ~ c ,i~ --.~.,. ~ j, .

Compounds of the invention may be a~",i";~ d by any suitable route, for example by oral, buccal, sub-lingual, rectal, vaginal, nasal, topical or parenteral (including intravenous, intramuscular, subcutaneous and i"' dWlUlldly) dliUII. Oral ddlllilli~IIdIioll is generally preferred.
For ad~,,i,,;_~,dIiu,, to man in the curative or prophylactic treatment of the disorders identified above, oral dosages of a compound of formula (I) will generally be in the range of from 0.5-8û0mg daily for an average adult patient (70kg). Thus for a typical adult patient, individual tablets or capsul~s containfrom 0.24ûûmg of active compound, in a suitable ~lldlll~r~P~ r,el.~t ~ e 1û vehicle or carrier, for a~l,,i,,iaI,dIiu,, in single or multiple doses, once or several times per day. Dosages for intravenous, buccal or sublingual ad~"i" dIiol, will typically be within the range of from û.14ûû mg per single dose as required. In practice the physician will determine the actual dosirlg regimen which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can be individual instances in which higher or lowar dosage ranges may be merited, and such are within the scope of this invention.
For human use, a compound of the formula (I) can be ddlllil 1' ' ~d alone, but will generally be ad",i"iaI leld in admixture with a pl,d""d..eutical carrier 2û selected with regard to the intended route of ddlllil' dliUII and standard IJlldlll ~ ltjr~l practice. For example, the compound may be d~lllill' ' ~d orally, buccally or sublingually, in the form of tablets CCII:~.;.lill.J excipients such as starch or lactose, or in capsules or ovules either alone or in admixture withexcipients, or in the fomm of elixirs or SUa~ llaiulla wllLdill;llg flavouring or colouring agents. Such liquid u, ~IJdl d~iUI li:~ may be prepared with plldllll~plltil~rlly ~.r,~ additives such as suspending agents (e.g.
methylcellulose, a semi-synthetic glyceride such as witepsol or mixtures of glycerides such as a mixture of apricot kernel oil and PEG~ esters or mixtures of PEG-8 and capryliclcapric glycerides). A compound may also be injected 3û ~al~l~t~,.. "y, for example intravenously, intramuscularly, subcutaneously or ill~lduululldlily. For parenteral ad~ d~iùll, the compound is best used in the form of a sterile aqueous solution which may contain other substances, for example salts, or ",u"osac-,l,d,ides such as mannitol or glucose, to make the solution isotonic with blood.

O WO 95/1997~ F~
'~1~3~7 Thus the invention provides in a further aspect a pl Idl "~dCe~.ltiCal ~III,UOailiUIl Wlll~liaill~ a compound of thr formula (I) together with a UIld",.~ tirAlly diluent or carrier th0refor.
There is further provided by the present invention a process of preparing a pl,d""ac~utical ccllluosiliù,~ u U~ JIiaill~ a compound of fommula (I) which proc3ss u u~ JI iaes mixing a compound of fommula (I) together with a pl,d""aceutically ~rr~ lr diluent or carrier therefor.
A compound of fonmula (I) may also be used in culllbilldLiùll with other therapeutic agents which may be usefui in the treatment of the above-",e"liu"ed disease states. The invention thus provides in another aspect a ~iOlllbilldii~
of a compound of formula (I) together with another therapeutically active agent.The coll~illdLiùll referred to ~bove may conveniently be presented for use in the form of a l,I,d""aceutical formulation and thus pl,d""a.eutical ulll~ùsi~iùlls w~ isi~y a CCIIILJilldliull as dehned above together with a plldlll~ 'y drCW~ le diluent or carrier comprise a further aspect of the invention.
The individual cull",on~,lLa a~f such a CulllLJilldLiull may also be a,il"i" ~:deither sequentially or simultaneously in separate IJI Idl 11 ,aceutical formulations.
Appropriate doses of known ~herapeutic agents for use in CUlllbilldLiUII with a compound of formula (I) will be leadily dppl~ ' ' -' by those skilled in the art.
Compounds of formula (I) may be prepared by any suitable method known in the art or by the following ,u, uuess~s which form part of the present invention. In the methods below R R1 ancl R2 are as defined in formula (I) above unless otherwise indicated.
Thus a process (A) for preparing a compound of formula (I) wherein R3 It~ SellLa hydrogen comprises treating a compound of formula (Il) R ~ ~CE~
(in which Alk l~ aellLa C1~al1kyl e.g. methyl or ethyl and Hal is a halogen atom e.g. chlorine) with a primary amine R1 NH2 in a suitable solvent such as an alcohoi (e.g. methanol or et~anol) or a mixture of solvents conveniently at a3û le",~,e, ~re of from 2ûC to reflux (e.g. at about 50C).
A compound of formula (Il) may conveniently be prepared by treating a compound of formula (Ill) W0 9~/1 9970 I' ~ . C - l o.~ --, , o R~OAlk R
with a haloacetyl halide (e.g. ~ uac~tyl chloride) in a suitable solvent such asa l~dlUyelldLe:d IlJ'dlUCdlLOn (e.g. I,i~l,lr,u",_;:,alle or diulllululll~;.ldll~), or an ~ther (e.g. tetrahydrofuran), preferably in the presence of a base such as an organic amine (e.g. a trialkylamine such as triethylamine) or an alkali metal carbonate or biCdluUlld~t: (e.g. NaHC03). The reaction may conveniently be effected at a temperature of from -20C to +20C (e.g. at about OC).
A compound of formula (I) may also be prepared from a compound of formula (Ill) in a two-step procedure via a compound of fonnula (Il) isolated without 1 0 purification.
Compounds of formula (I) may be prepared as individual t~lldllliUIII~I~ in two steps from the du,u,u,uridle er,d,,Liu,,,t,, of formula (Ill) or as mixtures (e.g.
1~:111..~.3) of either pairs of cis or trans isomers from the cu~ ,uonclull9 mixtures of either pairs of cis or trans isomers of fonmula (Ill).
Individual t:,,d,,liu,,,e,~ of the compounds of the invention may be prepared from Icll,l:llldlt:S by resolution using methods known in the art for the s_~d~iiull of racemic mixtures into their constituent ~lldllliUIII~ , for example using HPLC
(high pe,ru""d"ce liquid ~,IllUllldLUyld,Ully) on a chiral column such as Hypersil naphthylurea.
A compound of formula (Ill) may conveniently be prepared from a tryptophan alkyl ester of fommula (IV) R~ ¦--~OAlk (where Alk is as previously defined) or a salt thereof (e.g. the h~.ll u-,l llul ide salt) according to either of the following procedures (a) and (b). Procedure (b) is only suitable for preparing cis isomers of formula (Ill) and may be particularly suitable for preparing individual cis end"~iu",~,~ of formula (Ill) from D- or L-tryptophan alkyl esters as d,U,UI upri '~,.

O WO95/19978 I~,lII!;l~S.' _IOS
2l&l377 Procedure (a) This cr.,,,,ul i~es a Pictet-Spengler cyclisation between a compound of fonmula (IV) and an aldehyde R2CHO. The reaction may ca~nveniently be effected in a suitable solvent such as a l~dlù9~l~d~d h~nlluwluùl~ (e.g. di-,l,l~,u"",~l,d"e) or an aromatic hyd~ucd~uon (e.g. toluene) in the presence of an acid such as trifluoroacetic acid. The readion may ~I ~ iel llly be canried out at a temperature of from -20C to rellux to provide a compound of formula (111) in one step. The reaction may also be carried out in a solvent such as an aromatic ll~dlul,dlLJc,l~ (e.g. benzene or :oluene) under reflux, optionally using a Dean-Stark apparatus to trap the water produced.
The reaction provides a mixture of cis and trans isomers which may be either individual e,~d,,liu,,,a,~ or Id~ dl~a of pairs of cis or trans isomers deper,-l~l,y upon whether racemic or el Idl Itiullle~i ~Iy pure tryptophan alkyl ester was used as the starting material. IndividLlal cis or trans ~, Idl l~iUI I ~e~ :- may conveniently be separated from mixtures t~lereof by fractional ,, y ' " " , or by ~,lllullldLuyld~Jlly (e.g. flash column .,11lvllldlugld~ully) using ap,r"up~ ' solvents and eluents. Similarly, pairs of cis and trans isomers may be separated by ,lllullld~uyld,ully (e.g. flash column ulllullldluyla~Jlly) using d,U,UlU,UlidL_ eluents.
An optically pure trans isomer rrlay also be converted to an optically pure cis isomer using suitable ~Uilllt:riadliUII procedures. One such procedure comprises treating the trans isalmer or a mixture (e.g. 1: 1 mixture) of cis andtrans isomers with Ill~ll Idl lUIi~. 01' aqueous hydrogen chloride at a temperature of from 0C to the refluxing temperature of the solution. The mixture may then be subjected to l..lllUllldlUyldl.llly (e.g. flash column UIIIU~ ' _ d,UII~) to separate the resulting ~ia~ ù;~ulll~, or in the procedure utilising aqueous hydrogen chloride the desired cis isomer u,~ u;t~.~u., out as the hyiluul,lù~ir~e salt which may then be isolated by flltration.
Procedure (b) This c~,,,uliaes a four-step procedure from a compound of formula (IV) or a salt thereof (e.g. the h~,dlu,,lllulidt: salt). The procedure is particularly suitable for preparing a 1 R, 3R isomer c)f formula (111) from a D-tryptophan alkyl ester of fonmula (IV) or a salt thereof (e.g. the hyd,uul,lùricle salt). Thus, a first step (i) comprises treating a compoun~ of formula (IV) with an acid halide R2COHal (where Hal is as previously defined) in the presence of a base, e.yg. an organic W095119978 ~181377 r~ l83 base such as a trialkylamine (for example triethylamine), to provide a compound of formula (V) R~ ~;OALk H

The reaction may be conveniently carried out in a suitable solvent such as a l~al~gelld~ed h~lucdluull (e.g. d~ lulullle~llal~e) or an ether (e.g.
tetrahydrofuran) and at a temperature of from -2UOC to +40C.
Step (ii) comprises treating a compound of formula (V) with an agent to convert the amide group to a thioamide group. Suitable sulfurating agents are well-known in the art. Thus, for example, the reaction may conveniently be 1 û effected by treating (V) with L~ sc "'~ reagent. This reaction may conveniently be carried out in a suitable solvent such as an ether (e.g.
di~ u~ethane) or an aromatic h~dluwl~ull (e.g. toluene) at an elevated temperature such as from 40C to 80C to provide a compound of formula (Vl) Ro~OAlk H

Step (iii) c~",urises treating a compound of formula (Vl) with a suitable agent to provide a compound of formula (Vll) R ~ (Vll) (where Hal is a halogen atom, e.g. iodine). The reaction may c~ lllly be effected by treating (Vl) with an alkylating agent such as a methyl halide (e.g.methyl iodide) or an acylating agent such as an acetyi halide (e.g. acetyl chloride) in a suitable solvent such as a hdl~yc:l ' ' hy~, U~dl bul ~ (e.g.
~i-,l llul Ul I le~l Idl ,e) at an elevated temperature (e.g. under reflux).
In step (iv) the resulting iminium halide of fonmula (Vll) may be treated with areducing agent such as boron hydride, e.g. sodium borohydride, to provide the desired compound of formula (Ill). The reduction may conveniently be effected WO 9~119978 . P~.1~1, ,. lo~
~ 377 at a low temperature, e.g. within the range of -100C to 0C, in a suitable solYent such as an alcohol (e.g. methanol).
There is further provided by the present invention a process (B) for preparing a compound of fonmula (I), wherein R1 arld R3 together represent a 3- or 4-lc:tl alkyl or alkenyl chain, which process (B) comprises Cy~ d~iùl1 of acompound of formula (Vlll) ~k H RZ o wherein Alk l~p,~st:"L:, C,~alk;yl and R' and R3 together represent a 3- or 4-ll~lllb~l~d chain both as he~ ut:rule: described. The cyclisation is suitably carried out in an organic solvent or solvents, such as an alcoholic solvent (e.g.
methanol) and optionally an ethar solvent such as tetrahydrofuran, and in the prese~ce of a reducing agent, al~tly a palladium catalyst, such as palladium on carbon.
Cu,l~ "~ly a compound oF formula (Vlll) is prepared by reaction of a compound of formula (Ill) as he, t,i"L~rul ~ described with a compound of formula (IX) R' N-R
o wherein Hal " y,t,ae,~ a halogen atom as l~e~ u_Ful~ described, R' and R3 together represent a 3- or 4-l l lel l ~be~ e :d chain as l l~ described and R~
,e~ S";;, a protecting group, suitably a benzylo~tycarbonyl group or the like.
Typically the reaction is carried out in a ~,III~Iil ' organic solvent, such as Ji.,l llc l t," l~il Idl ,e, and a tertiary amine, such as triethylamine or the like.
According to a further aspect of the present inve~tion, there is provided a process (C) for preparing a com30und of formula (I) wherein R3 ~cs~ t,"L~ C, 3alkyl, which process comprises t:yclisation of a compound of formula (X) WO 9~ 9978 ~ 1 ~ t~ .1/~1 7r,~ _ 18.7 218~377 ~OAIk R' ~ ~ N ~ R
vlherein Alk l~,urt:s~llL:~ C,calkyl as l~el~ rul~ described and Rs It:,UI~:5t:fl;;-C2~alkyl, sl~hstit~tad at C1 by a halogen atom, the halogen atom being as h~ i,lL~rul~ described. Suitably the cyclisation is achieved by reflux for many hours, such as 22 to 26 hours, in the presence of an ether solvent, such as tetrahydrofuran, and a suitable amine as he,~i"drl~, described in the a~",,ud"ying examples.
Aptly a compound of fommula (X) can be prepared from a compound of formula (Ill) by suitable acylation techniques, such as reaction with a CJ4carboxylic acid, .C~hQtit~ c! at C2 by a halogen atom in a organic solvent, such as ~i.,l ,lul u,, I~:ll Idl ,e.
Compounds of formula (I) may be converted to other compounds of formula (I). Thus, for example, when R2 is a Q~hstit~' ' benzene ring it may be necessary or desirable to prepare the suitably qllhQtitl~t~d compound of formula(I) subsequent to process (A), (B) or (C) as above. Examples of d~,UlU,Ulidl~:
i" wll~crsions include nitro to amino or aralkyloxy to hydroxy by suitable reducing means (e.g. using a reducing agent such as SnCI2 or a palladium catalyst, such as palladium-on-carbon), or amino to sl~hstit~ amino such as acylamino or sulphonylamino using standard acylating or sulphonylating conditions. In the case where R2 ~,ul~ a s~hsti' ~' ~ bicyclic system, suitable interconversion can involve removal of a substituent, such as by treatment with a palladium catalyst (e.g. palladium-on-carbon) whereby, for example, a benzyl substituent may be removed from a suitable bicyclic system.
The ~JI,d""a,,~utically ~ le acid addition salts of the compounds of formula (I) v~.hich contain a basic centre may be prepared in a C~ll~ iulldl manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
Plldlll~ "y ~ccP~ le base addition salts may be obtained in an O wo g~,l9978 ~ . 3 ~ 7 ! ~ ~ r~ o~

analogous manner by treating ~3 solution of a compound of formula (I) with a suitable base. Both types of sslt may be formed or il~Lt:luu~ d using ion-exchange resin techniques.
Compounds of the inventiorl may be isolated in acco~ with solvent molecules by cry:,L~ .iu" from or evaporation of an d~UIJI u,o~i solvent.
Thus, according to a further aspect of the invention, we provide a process for preparing a compound of formula (I) or a salt or solvate (e.g. hydrate) thereof which t~",~u,i:,es process (A), (B) or (C) as he,-;i"L~c:rult, described followed by i) an interconversion steF); and/or either ii) saltformation; or iii) solvate (e.g. hydrate) f~rmation.
There is further provided by t~le present invention compounds of formulae (Il), (Vlll), (X) and further cûmpûuntis of formulae (Ill), (V), (Vl) and (Vll), with the exception for compounds (Ill), ('V), (Vl) and (Vll) wherein R is hydrogen, R2 jS
phenyl and Alk is methyl.
The synthesis of the compoullds of the invention and of the illL~IllleJidlt:s for use therein are illustrated by the following, non-limiting Examples. In the Examples section l1e, t:i, IdrLer the following abbreviations are used:
2û DMSO (dimethylsulphoxide), MeOH (methanol), EtOH (ethanol), DMF
(dimethy;'_ " Idl I ~iJ~), EtOAc (et~yl acetate) and THF (L~ dl l,lr~l ufuran).
111' 111alJidLe:5 1 and 2 Methvl 1.2.3.4-tetrahvdro-1-(3.4-methvle,leJiu,~vPhenvl~-9H-pvrido~3~4 blindole-3-carboxvlate, cis and trans isomers To a stirred solution of racemic tryptophan methyl ester (13 9) and piperonal (9.7 9) in anhydrous CH2CI2 (300 mL) cooled at 0C was added dropwise trifluoroacetic acid (9 mL) and the solution was allowed to react at ambient t~,.,,,u~, Ire. After 4 days, the yellow solution was diluted with CH2C12 (100 mL), washed with a saturated aqueous solution of NaHCO3, then with water and dried over Na2SO4. The organic layer was evaporated to dryness under reduced pressure and the residle was purified by flash ,1 llullldLuyl d,ul ,; eluting with CH2CI2/MeOH (99/1 ) to gi~e first II l~ JidL~ 1. the cis isomer (6.5 y9) m.p.
: 90-93C followed by l"L~"",eJi~L~ 2. the trans isomer (6.4 9) m.p.: 170C.

W09~/19978 218~ 371 r~ r7~l 183 The following compounds were obtained in a similar manner:
"~d,~ 3 and 4 Methvl 1.2.3.4-tetrahvdro-1-(4-methoxvPhenvl)-9H-Pvridor3.4-blindole-3-c~, ~u,~/ cis and trans isomers The same method but starting from racemic tryptophan methyl ester and 4-methox~Le"~dlde,l,yde gave l"~""eu';.'~ 3 the cis isomer as white crystals m.p.: 142C and Ill~ didl~ 4 the trans isomer as white crystals m.p.: 209-21 0C.
I"~""edi Methvl 1.2.3.4-tetrahvdro-1-(3-methoxvPhenvl)-9H-pvridor3~4-b1indole-3 c dl ~u ~YIdL~ cis isomer The same method but startin~ from racemic tryptophan methyl ester and 3-methoxyLt~ dl~ yde gave the title comPound as white crystals m.p.: 146C.
Illlt:lllledid~s 6 and 7 Methvl 1.2.3.4-tetrahvdro-1-(4-ethoxvPhenvl~-9H-pvrido~3.4-blindole-3-carboxvlate. cis and trans isomers The same method but starting from racemic tryptophan methyl ester and 4-ethoxyb~ dld~l ,yde gave l"le""edidl~ 6 the cis isomer as white crystals m.p.:
1 80C and II ,I~" "e~ 7 the trans isomer as white crystals m.p.: 196-1 98C.
Ill'~ .Illt:did~t:s 8 and 9 Methvl 1 2.3.4-tetrahvdro-1 -(2.3-dih~,d, uue"~orblfuran-5-vl)-9H-Pvridor3 4-blindole-3-carboxvlate. cis and trans isomers The same method but starting from racemic tryptophan methyl ester and 2 3-di~.yd~ ubel ,~u[b]furan-5- cdr~u,~alclel ,yde gave ll lie:l I"o 8. the cis isomer as white crystals m.p.: 106-109C and Il~ id~t: 9. the trans isomer as v"hite crystals m.p.: 21 9-222C.
Ill'~ l,)~;.,t~ 10 and 11 Methvl 1 .2.3.4-tetrahvdro-1 -(3.4-eth~ ediu~vPhenvl)-9H-Pvridor3~4-blindole-3 carboxvlate. cis and trans isomers -WO gS/19978 ~ ~ 8 ~ 3 7 7 P~ io~

The same method but starting from racemic tryptophan methyl ester and 1,4-~ell u.liu~dll-6-c,dlbo.dld~lyde gave ~ .Jidl_ 10. the cis isomer as white crystals m.p.: 104-106C ancl l"L~",e.lidl~ 11, the trans isomer as white crYstals m.p.: 207-209C.

I" , l le~ 12 Methvl 1 .2.3.4-tetrahYdro-1-(2- ,l llul uPIl~l IYI)-9H-Dvridor3.4-blindole-3-Cdl bU~VIdlt:, mixture of cis and tlans isomers The same method but starting from racemic tryptophan methyl ester and 2-1û ul~lu~uLt:~ clld~yde gave the title comPound as white crystals m.p.: 154C.
,llledidlt,s 13 and 14 Methvl 1 .2.3.4-tetrahvdro-1 -(4-cl~lul uul ,t ",~1)-9H-ovridor3.4-blindole-3-carboxvlate, cis and trans isomers The same method but starting from racemic tryptophan methyl ester and 4-,1 lluluLe~ I dld~l ,yde gave ll ,~c:""e~idl~ 13. the cis isomer as white crystals m.p.
: 208-209C and Illl~ll"~did~ 4, the trans isomer as white crystals m.p.: 108-1 09C.
I" ~",ledidl~s 15 and 16 Methvl 1 .2.3.4-tetrahYdro-1 -(3,4-di.,l llol u,~ 1)-9H-oyridor3,4-blindole-3-carboxvlate, cis and trans isomers The same method but starting From racemic tryptophan methyl ester and 3,4-di~ lub~ll dld~llyde gave Ill ~,lll~did~tl 15. the cis isomer as a white solid 1H
NMR (CDCI3) ~ (ppm): 7.8-7 (m, 8H, H aromatic); 5.15 (brs, 1H, H-1); 3.9 - 3.8 (dd, 1H, H-3) 3.7 (s, 3H, CO2C~3); 3.2 - 3.1 (ddd, 1H, H-4) 2.9 (m, 1H, H-4);
2.4 (brs, 1H, NH) and l"I :""e-lidlt: 16, the trans isomer as a white solid m.p.:
204C.
Ill~ .lidLtl 17 Methvl 1 .2.3.4-tetrahvdro-1-(1 .2.3.4-tetrahvdro-6-naPhthvl)-9H-ovridor3.4-blindole-3-carboxvlate. cis isomer The same method but starting frl~m racemic tryptophan methyl ester and 1,2,3,4-tetrah~,u,ldul,ll,yl-6- _dlbu dld~llyde gave the title comoound as a white solid1H NMR (CDCI3) ~ (ppm): 7.7-7(m, 8H, H aromatic); 5.2 (s, 1H, H-1); 4.0 (dd, WO 95/19978 ~ 1 ~3 13 ~ 7 P~~ 7r~ 18~ --1H, H-3); 3.8 (s, 3H, CO2CH3); 3.2 (m, 1H, H-4); 3.0 (m, 1H, H-4); 2.7 (m, 4H, CH2Ar); 1.7 (s, 4H, CH2CH2Ar) l~Itt~ did~c~s 18 and 19 Methvl 1 .2.3.4-tetrahvdro-1 -(2-naphthvl)-9H-ovrido~3.4-blindole-3~, bo~ldl~, cis and trans isomers The same method but starting from racemic tryptophan methyl ester and 2-rld~lltlldld~llyde gave Illldlllledidld 18, the cis isomer as a white solid 1H NMR
(CDCI3) ~ (ppm): 8-6.9 (m, 1 2H, H aromatic); 5 4 (s, 1 H, H-1 ); 3.95 (dd, 1 H, H-

3); 3.7 (s, 3H, CO2CH3) 3.2 (ddd, 1H, H-4); 3 (m, 1H, H-4); 2.5 (brs, 1H, NH) and Illll~llllt:didLt~ 19, the trans isomer as a white solid (0.6 9) m.p.: 119C.
I,llc:""e~id~s 20 and 21 Methvl 1.2.3.4-tetrahvdro-1-(2-thienvl)-9H-Pvrido~3~4-blindole-3-carboxvlate~ cis and trans isomers The same method but starting from racemic tryptophan methyl ester and 2-11 ,iù~l ~el1ecdl l,u,~dl-;lel ,yde gave ll ,t~. " I_didl_ 20. the cis isomer as a pale yellow solid m.p.: 134-137C and l"l~""eJidl~ 21. the trans isomer as white crystals m.p. :169C.
lddidL~s 22 and 23 Ethvl 1,2.3.4-tetrahvdro-1-(3-thienvl)-9H-pvrido~3.4-blindole-3-cdll,uAvl_~,. cis and trans isomers The same method but starting from racemic tryptophan ethyl ester and 3-ll ,iopl~e,1ecd, L,u~al~t:l ,yde gave ll llt:l " ,~ 22, the cis isomer as white crystals m.p.: 13ûC and Illl~ll,lddidl~: 23. the trans isomer as white crystals m.p. :182-1 84C.
ledidLt5s 24 and 25 Methvl 1.2.3.4-tetrahvdro-1-(5-bromo-2-thienvl)-9H-pvrido~3,4-blindole-3-r~d~bo~latc, cis and trans isomers The same method but starting from racemic tryptophan methyl ester and 5-.
bromo-2-ll,iùpl~enecdlb~dld~llyde gave lll' ",ed, ~_ 24. the cis isomer as a cream solid m.p.: 130C and IIlLt:llll~didld 25. the trans isomer as a cream solid m.p.: 205CC.

1~ wo 95/19978 2 i 8 1 3 7 7 ~ ~ io~

llledidlc:s 26 and 27 Methyl 1,2.3.4-tetrahvdro-1-(4-bromo-2-thienvl))-9H-pvrido~3.4-blindole-3-carboxvlate, cis and trans isomel-s The same method but starting from racemic tryptophan methyl ester and 4-bromo-2-ll,iopl)el~ecd,l,~"~dl~ l,yde gave l"le""edid~e: 26. the cis isomer as acream solid m.p.: 200C and Ill'~.lll~didl~ 27. the trans isomer as a cream solid m.p.: 120C.
Il lt~ iidl~ 28 Methvl 1.2.3.4-tetrahvdro-1-(3-furvl)-9H-Pvrido~3.4-blindole-3~arboxvlate.
mixture of cis and trans isomers The same method but starting from racemic tryptophan methyl ester and 3-furaldehyde gave the title compound as a yellow solid m.p.: 1 30C.
I"tenllledidl~s 29 and 30 Ethvl 1.2.3.4-tetrahvdro-1-(5-methvl-2-furvl)-9H-Pvridor3~4-blindole-3 carboxvlate, cis and trans isomers The same method but starting from racemic tryptophan ethyl ester and 5-methylfurfural gave l~ , ",edidl~ 29. the cis isomer as a oily compound 1 H NMR
(CDCI3) ~ (ppm): 7.7 (brs, 1H, ~H indole); 7.5 (d, 1H, H aromatic); 7.25-6.9 (m,3H, H aromatic); 6.15 (d, 1H, H aromatic); 5.85 (m, 1H, H aromatic); 5.25 (brs, 1H, H-1); 4.2 (q, 2H, CO2CH2CI13); 3.8 (dd, 1H, H-3); 3.2 - 2.8 (m, 2H, H-4); 2.2 (s, 3H, CH3); 1.25 (t, 3H, CO2CH2CH3) and Illlt:lll.~ ' 30, the trans isomer as a cream solid m.p.: 1 52C.
Il ,t~,""e.i,.~t~,~ 31 and 32 Ethvl 1,2,3.4-tetrahvdro-1-(4-"~ e"~ -9H-pvrido~3,4-blindole-3-Cdl~u,~ ' cis and trans isomers The same method but starting from racemic tryptophan ethyl ester and p-tolualdehyde gave ll ,l~ ~ "edidlt, 31. the cis isomer as white cr-ystals m.p.: 1 48C
and ll l'~. l l l~didlt: 32. the trans isomer as white crystals m.p.: 1 80C.
Ill~ell"edidlt::, 33 and 34 ~181377 WO 95/19978 ~ F~ .C-lo.~ l Methvl 1,2,3,4-tetrahvdro-1-(3-methvlDhenvl)-9H-pvrido~3,4-blindole-3-carboxvlate, cis and trans isomers The same method but starting from racemic tryptophan methyl ester and m-tolualdehyde gave I~ did~ 33. the cis isomer as white crystals 1H NMR
(CDCI3) ~(ppm): 7.6-7 (m, 9H, H aromatic~; 5.2 (brs, 1H, H-1); 4-3.9 (dd, 1H, H-3) 3.8 (s, 3H, CO2CH3); 3.2 - 3.1 (ddd, 1H, H-4) 3 (m, 1H, H-4); 2.35 (s, 3H, CH3); 1.7 (brs, 1 H, NH) and ll ~ l ,e-lidlt: 34. the trans isomer as a white solid m.p.: 175C.
Il ,t~_, l l lt ~idlt s 35 and 36 Methvl 1.2.3.4-tetrahvdro-1-(4-trifluoromethvlDhenvl)-9H-Pvridor3,4-blindole-3-carboxvlate. cis and trans isomers The same method but starting from racemic tryptophan methyl ester and ~
trifluoromethyl.,~ dld~l ,yde gave ll ,lt:l ",~lidle 35. the cis isomer as pale yellow crystals m.p. . 190C and I~ edidl 36, the trans isomer as pale yellow crystals m.p.: 203C.
I"~""edidl~:s 37 and 38 Ethvl 1~2~3l4-tetrahvdro-1-(4-cvanoDhenvl)-9H-Dvrido~3~4-blindole carboxvlate, cis and trans isomers The same method but starting from racemic tryptophan ethyl ester and 4-c~.l"uL~",:dldel ,yde gave ll l ~ did~e 37. the cis isomer as white crystals m.p.
: 200C and ll "el 1"edidl~ 38, the trans isomer as white crystals m.p.: 1 56C.
II l~,, l l It ~idll: 39 Methvl 1.2.3.4-tetrahvdro-1-(4-hvdroxvphenvl)-9H-ovrido~3,4-blindole-3-carboxvlate. cis isomer The same method but starting from racemic tryptophan ethyl ester and 4-hydroxyL,~"~dldeh~de gave the title comDound as pale yellow crystals 1 H NMR
(DMSO) ~(ppm): 10.3 (s, 1H, NH-indole) 9.4 (s, 1H, OH); 7.8 - 7.5 (m, 8H, H
aromatic); 5.1 (brs, 1H, H-1); 3.9 (m, 1H, H-3); 3.75 (s, 3H, CO2CH3) 3.1 (m, 1H, H-4); 2.8 (m, 1H, H-4).
l~t~"edid~e 40 O WO 95/19978 ~ 3 7 ~ o.s Methvl 1,2,3,4-tetrahvdro-1-(3-llvdroxv-4-methoxvPhenvl)-9H-Pvridor3.4-blindole-3-carboxvlate, cis isomer The same method but starting from racemic tryptophan methyl ester and 3-hydroxy-4-methoxybe, l~dldt:l ,yl~e gave the title comPound as a yellow so~id m.p.
: 1 40-1 48C.
lltdidl~ 41 Methvl 1.2.3,4-tetrahvdro-1-(4-llvdroxv-3-methoxvPhenvl~-9H-Pvridor3.4-blindole-3-carboxvlate, cis isonler The same method but starting from racemic tryptophan methyl ester and 4-hydroxy-3-methoxybe, I~dld~l ,yde gave the title compound as a cream solid m.p.
: 195C.
I"'~. " ,eu~dl~ 42 Methvl 1.2.3.4-tetrahvdro-1-(4-ethvlPhenvl)-9H-Pvridor3~4-blindole-3 carboxvlate. cis and trans isomers The same method but startin~ from racemic tryptophan methyl ester and 4-ethyll,~"~dldel ,yde gave the cis and trans isomer of the title compound.
Cis isomer: white solid 1 H NMR (CDCI3) ~(ppm): 7.65-7.1 (m, 9H, H aromatic);
5.25 (brs, 1H, H-1 ); 4(dd, 1H, H-3); 3.9 (s, 3H, CO2CH3); 3.4 (ddd, 1H, H-4);
3.1 (m, 1H, H-4); 2.7 (q, 2H, C_2CH3) 1.4 (t, 3H, CH2CH3).
Trans isomer: white solid m.p.: 187C.
Il,' Illedidlt:s 43 and 44 Methvl 1.2.3.4-tetrahvdro-1-(4-isoProPvlPhenvl)-9H-pvridor3~4-blindole-3 carboxvlate, cis and trans isomers The same method but starting from racemic tryptophan ethyl ester and 4-isol,, u~J~;.bt~ dl ;Itll ,yde gave l"l~" "e,iidle 43. the cis isomer as a white solid 1 H
NMR (DMSO) ~(ppm): 1 0. 1 5 (s, 1 H , NH indole); 7.3-6.7 (m, 8H, H aromatic); 5(brs, 1H, H-1); 3.6 (m, 1H, H-:3); 3.5 (s, 3H, CO2CH3); 2.95-2.5 (m, 3H, H-4 +
CH-(Me)2) 2.4 (brs, 1H, NH); 1(d, 6H, 2xCH3) and Illlt:ll"- " ' 44. the trans isomer as a white solid m.p.: 189C.
Il l'~ ' ' Itldidlt:s 45 and 46 WO 95/19978 ~ 3;7 7 r~ l83 EthYI 1~2~3~4-tetrahvdro-1-(4-nitrophenvl)-9H-pvrido~3~4-blindole-3-carboxvlate~cis and trans isomers The same method but starting from racemic tryptophan ethyl ester and 4-r,il,ubc,,~dl~ l,yde gave IIlL~ didle 45, the cis isomer as yellow crystals m.p.: 1 68C and ll l~c", ledidl~ 46. the trans isomer as yellow crystals m.p.: 1 95C.
Il ~tcl " ,e.lid~e 47 Ethvl 1,2,3,4-tetrahvdro-1-(4-dimethvld",i"o~l)e"~l)-9H-Pvrido~3.4-b1indole-3-carboxvlate, mixture of cis and trans isomers The same method but starting from racemic tryptophan ethyl ester and 4-dimethyld",i"obe"~dldel,yde gave the title comDound as white crystals m.p.:
1 70C.
I"t~,.",edidl~s 48 and 49 Ethvl 1.2.3.4-tetrahvdro-1-(3-pvridvl)-9H-pvridor3.4-b1indole-3-carboxvlate, cisand trans isomers The same method but starting from racemic tryptophan ethyl ester and 3-pyli~illeCdluu~dldcl~yde gave l"~e"",e.lidle 48. the cis isomer as pale yellow crystals m.p. : 23û-232C and ll I~Cl " ,edidl~ 49. the trans isomer as white crystals m.p.: 210-214C.
11l I"e.lidlc~ 50 and 51 Methvl 1,2,3,4 tetrahvdro-6-fluoro-1-(3.4-methvlenedioxvPhenyl)-9H-pvrido~3~4 blindole-3-carboxvlate. cis and trans isomers The same method but starting from racemic 5-fluoro-tryptophan methyl ester and piperonal gave l,,Lc,~,,e.lidl~ 50. the cis isomer as a cream solid m.p. :60C
and ll ,Ic, " ,e,iidl_ 51, the trans isomer as a cream solid m.p.: 21 3C.
Il,.c,,,,edidlcs 52 and 53 Methvl 1.2.3.4-tetrahvdro4-fluoro-1-(4-~"~Ll~u~ c"~l)-9H-Pvrido~3~4blindole 3-carboxvlate, cis and trans isomers The same method but starting from racemic 5-fluoro-tryptophan methyl ester and 4-methoxybenzaldehyde gave Intermediate 52. the cis isomer as a solid 1 H
NMR (CDCI3) ~ (ppm): 7.4~.8 (m, 8H, H aromatic); 5.15 tbrs, 1H, H-1); 3.9 ~ WO 95/19978 ~ 1 ~ 1 3 7 7 ~ /r.1 75.'~ lo~

(dd, 1H, H-3) 3.8 (s, 3H, CO2CH3); 3.2-2.9 (m, 2H, H-4) and ~ eldidLt~ 53, the trans isomer as a solid m.p.: 1 97C.
I"l~""edid~s 54 and 55 (1 R,3R)-Methvl 1 .2.3.4-tetrahvdro-1-(3.4-methvl~, ,ediùA~Phenvl)-9H-Pvridor3~4blindole-3-carboxvlate, cis isomer and (1 S.3R)-methvl 1 ,2,3.4-tetrahvdl-o-1 -(3.4-methvl~ iùAvPhenvl)-9H-Pvridor3~4 blindole-3-carboxvlate trans isolner To a stirred solution of D-trypto~han methyl ester (11 9) and piperonal (7.9 g) in anhydrous CH2CI2 (400 mL) c~oled at 0C was added dropwise trifluoroacetic acid (7.7 mL) and the solution was allowed to react at ambient Lell~,uc~ re.
After 4 days, the yellow solution was diluted with CH2CI2 (200 mL) and washed with a saturated aqueous solution of NaHCO3, then with water (3x200 mL) and dried over Na2SO4. The organic layer was evaporated under reduced pressure and the residue was purified by flash ,lllUll~d~ 71d~ eluting with ,di.,l,lc"u"n~ al~e/ethyl acetate (97/3) to giYe first ll~t~ ledidlts 54, the cis isomer (6.5 g) m.p.: 154C followed b~ Ill~tllll1.311idl~ 55, the trans isomer (8.4 g) m.p.:
1 88C.
The following compounds were obtained in a similar manner:
I l l~e:l 11 I~I~idl~l 56 (1S, 3S) Methvl-1.2.3.4-tetrahvc~ro-1-(3.4-methvl~l-ediu,cvPhenvl)-9H-Pvridor3.4-blindole-3-carboxvlate. cis isomer and (1R. 3S) methvl-1,2.3.4-tetrahvdro-1-(3.4-lllt~ ,-ediu,~vPhenvl)-9H-Pvridor3.4-blindole-3-carboxvlate, trans isomer The same method but starting from L-tryptophan methyl ester and piperonal gave the cis and trans isomers of the title comPound.
Cis isomer: white cr,Ystals m.p.: 1 54C.
Trans isomer: white crystals m.p.: 187-189C.
lllledidle:~ 57 and 58 - (1 R,3R)-Methvl 1 ,2,3,4-tetrahvciro-1 -(4-methoxvPhenvl)-9H-pvridor3,4-blindole-3-carboxvlate, cis isomer and -~1377 W0 95119978 ` ~ P~ .. l 18 (1S.3R)-methvl 1,2,3,4-tetrahvdro-1-(4-methoxvphenvl~-9H-ovrido~3,4-blindole-3-wrboxvlate. trans isomer The same method but starting from D-tryptophan methyl ester and 4-methoxyut~ dl.lt:l,yde gave l"le""edidld 57. the cis isomer as white crystals m.p.: 124-125C and Illlc:""e.liald 58. trans isomer as white crystals m.p.: 219-2ZC.
I"~.",ed; 'u3 59 and 60 (1R, 3R)-Methvl 1.2.3.4-tetrahvdro-1-(3-chloro-4-methoxvphenvl~9H-Pvrido~3,4-blindole-3-~àl~u~vlatc, cis isomerand (1 S. 3R)-methvl 1 ,2,3.4-tetrahvdro-1 -(3-chloro-4-methoxvphenvl) 9H-Pvridor3,4-blindole-3-carboxvlate. trans isomer The same method, but starting from D-tryptophan methyl ester and 3-chloro-4-methoxy~"~dld~l,yde gave I~ lllledidlt7 59. the cis isomer isolated as the I,Jd,u~,l,lu,ide salt as white crystals m.p.: 20ûC and ll,t.,,ll,ddidlt: 60. the trans isomer as white crystals m.p.: 164C.
Il,t.,.",edidlt,s 61 and 62 (1 R,3R)-Methvl 1 .2,3,4-tetrahvdro-1-(2. 3-dihvd, uu~ ù~t~lfuran-5-vl)-9H
Pvrido~3.4-blindole-3-carboxvlate. cis isomer and (1S,3R)-methvl 1,2,3,4-tetrahvdro-1-(5-(2.3-dihvdrobenzo~blfuran))-9H-Dvrido~3.4-blindole-3-carboxvlate. trans isomer The same method but starting from D-tryptophan methyl ester and 2,3-dih~dlub~ u[b]furan-5-cd~L,u~dlcl~llyde gave Ill~u""~ , 61. the cis isomer as white crystals m.p.: 282C and l"l~""e~.. 'u 62, the trans isomer as white crystals m.p.: 204C.
ll~t~..lll~did~ a 63 and 64 (1R,3R)-Methvl 1.2.3,4-tetrahvdro-1-(5-indanvl)-9H-Pvrido~3~4-blindole-3 Cdl uuAvl.~tc cis isomer and (1S.3R)-methvl 1.2.3.4-tetrahvdro-1-(5-indanvl)-9H-Dvrido~3.4-blindole-3-cwrboxvlate trans isomer The same method but starting from D-tryptophan methyl ester and indan-5-w,~u,~dl~dhyde gave Ill~ L~ 63, the cis isomer as white crystals m.p.:
35 1 3û-131 C and ll ll~l 1 "edidle 64. the trans isomer as white crystals m.p.: 1 96C.

O WO9~/19978 ~181377 r~ 183 Il, ",edid~e 65 Ethvl 1 .2.3.4-tetrahvdro-1 -(4-trifl~u, u" le:tl ,~AvPhenvl)-9H-Pvridor3.4-blindole-3-carboxvlate. cis and trans isomels The same method but starting from racemic tryptophan ethyl ester and 4-trifluu, u" ~ l ,uAybe"~dll~,yde gave cis and trans isomers of the title compound.
Cis isomer: white crystals m.p.: 88C.
Trans isomer: white crystals m.p. :152C.
1 û ll ~UI " ,e.Jidle 66 Methvl 1.2,3.4-tetrahvdro-1-(5-methvl-2-thienvl)-9H-pvrido r3.4-blindole-3-cd,~uA~latc, cis and trans isomers The same method but starting from racemic tryptophan methyl ester and 5-methyl-2-ll,iu~ullel~ecd,l,oxdld~:l,yde gave the cis and trans isomers of the title 1 5 compound.
Cis isomer: oily compound 1 H NIMR (CDCI3) ~ (ppm): 8.4 (brs, 1 H, NH-indole);
7.7 - 6.6 (m, 6H, H aromatic); 5.5 (brs, 1H, H-1); 3.9 (dd, 1H, H-3); 3.85 (s, 3H, CO2CH3); 3.3 - 2.9 (m, 2H, H-4); 2.5 (s, 3H, CH3).
Trans isomer: white crystals m.p.: 194C.
2û
l"~" "~ s 67 and 68 (1 S.3R)-Methvl 1.2. 3.4-tetrahvdro-1 -(3.4-methvl~, ,ediuA~rPhenvl)-9H-Pvridor3~4 blindole-3-cdl~ù,~ld~e and (1R.3R)-methvl 1.2.3.4-tetrahvdro-1-(3.4-,~ e-JioA~/Phenvl)-9H-Pvridor3~4 blindole-3-carboxvlate To a stirred solution of D-tryptophan methyl ester (obtained by treating the wllt:a,uulluill~ h~dluulllulidt: salt in water with saturated aqueous NaHC03 solution and extraction with CH2CI2) (25.79) and piperonal (19.4g) in anhydrous di.,l,lu,u,,,~Ll,d,,e (7ûûml) cooled to ûC was added dropwise trifluoroacetic acid 3û (18.1ml) and the solution was allowed to react at 4C. After 5 days, the yellow solution was diluted with diul~lu~u~ dne (5ûûml). The organic layer was washed with a saturated aqueous solution of NaHCO3, then with water (3 x 5ûûml) until the pH was neutral and dried over Na2SO4. The organic layer was evaporated under reduced pressure to a volume of about 5ûûml. The trans-. 35 isomer, \,vhich crystallised, was filtered and the filtrate was reduced to 20ûml.

wO gS/19978 2 ~ ~ 1 3 ~ 7 ~ .8j --Another fraction of the trans-isomer ~Iy~dlli~t:d. The fractions of trans-isomerwere combined to give the (1S,3R) isomer, I~ llediale 67, as v~hite crystals (1 1 .49).
mp: 1 88DC
[a]r~20 - +32.4 (c = 1.03, CHCI3).
The filtrate cu, l~dil lil l9 mainly the cis-isomer was reduced to 1 OOm~ and isopropyl ether (200ml) was added. Upon cooling, the (1R,3R) isomer, I~ ""edidl~ 68, uy ' " ~ ~. as a white solid (17.49).
mp: 154-1 55C
[a]r~20 = + 24.4 (c = 1.03, CHCI3).
I"~,""edid~ 69 (1R.3R)-Methvl 1.2.3.4-tetrahvdro-1-(3.4-methvl~.Ie~iu,~ "vl)9H-Pvridor3.4-blindole-3-carboxvlate Method A
Il, ",edidL~ 67 (5.û9) was dissolved in methanol (150ml). Hydrogen chloride was bubbled into the solution for several minutes at 0C and the resulting yellow solution was refluxed for 24 hours. The solvent was removed under reduced pressure and the residue was basified with a saturated aqueous solution of NaHC03 and extracted with diulllolulllt:llldlle. The organic layer was washed with water, dried over Na2S04 and purihed by flash ,I)lullldLuylaully eluting with ,ii.,l,lo,u,,,t:~l,dne/methanol (99/1) to give the title comoound (2.39) Co"t~ uUI ~di"~ to an authentic sample of l"~", I/~:did~e~ 68.
Method B
l~tt:""edid~e 67 (259) was heated in 1N h~ldluulllulic acid (78.5ml) and water (400ml) at 60C for 36 hours. From the initial pale yellow solution, a white solid ,ule:~.ipi~a~:d. The mixture was then allowed to cool to 0C and the solid filtered.
The solid was then washed with diisopropyl ether (3 x 200ml) and dried to give the h~dl uul 11~ salt of the title comPound (209) as a v~hite solid.
mp (dec.): 2û9 - 212C
Method C

O WO 9S/19978 ';2 1 ~ ~ 3 7 7 p l/r~

A 1: 1 mixture of the cis and tré~ns isomers of I~ ledid~es 54 and 55 (29) was heated in 1 N h),ul u.,l lltJI ic acid (6.8ml) and water (1 5ml) at 5ûC for 72 hours. A
similar work-up as described in Method B above gave the h~ u.,l llù, itle salt of the title compound (1 79) as a ulhite solid Il llel " ,e~lidle 7û
~R)-Na-(3.4-Methvlenedioxvr~henvlcarbonvl)-trvDto~han methvl ester To a suspension of D-tryptt~phan methyl ester hy~l u-,l llul iJe (1 û.2g) in anhydrous CH2C12 (15ûml) caoled at 0C was added dropwise ~,k,l~.yl~.."i"e 1û (12.3ml). To the resulting solution solid piperonyloyl chloride (8.169) was added portionwise at the same temperature, and the mixture was stirred at room temperature for 2 h. The mixl:ure was washed succes~ 'y with water, 0.5N
I~IJluui~luric acid, water, a satl~rated aqueous solu~ion of NaHC03 and again with water. After drying over Na2SO4 and evaporation of the solvent under reduced presure, the resulting oil on trituration from hot cy~.lul"3,~d"e afforded the title comPound as a white solid (14.79).
mp: 123-124C
[a]D2 = 84 4 (c = 1 04, CHCI ~) "",e~idle 71 (R)-Na-(3~4-Methvlenedioxvohenvll; liOCdl uu"~I)-trvDtor~han methvl ester A mixture of Illlelllledidl~ 70 (149) and L~..t-,3~u"'s reagent (9.289) in di,,,e~l,uxjethane (280ml) was heated at 60C under N2 for 16 hours with stirring. The reaction mixture was evaporated to dryness and the resulting oil was dissolved in ethyl acetat~3, then washed successively with an aqueous saturated solution of NaHCO3 and water and dried over Na2SO4. The oily residue obtained after evaporation under reduced pressure gave, on trituration from cy.,lul le,~dl~e, a yellow po~vder which was filtered and washed with cooled methanol to afford the title coml~ound (9.749).
mp: 129-130C
[a]D =-186.8 (c= 1 14, CHC13) lI ~Lt~ e~lid~e 72 W0 9S/19978 ~ 1 8 ~ 3 7 7 ~ ~7s~ o~ --(1 R.3R)-Methvl 1 .2.3.4-tetrahvdro-1 -(3.4-methvlenedioxvPhenvl)-9H-pvrido~3,4-blindole-3-carboxvlate A solution of I~ iidl~ 71 (99) and methyl iodide (10ml) in anhydrous iil,lllUlUllle~llldlle (200ml) was heated at reflux under an argon `~lluaullt~ with protection from light. Affer 24 hours, the solvent was removed under reduced pressure to give an orange oil which on trituration from hexane gave a soiid which was washed with ether and used without further purification in the next step. This compound (13.119) was dissolved in methanol (250ml) and the solution was cooled to -78C. NaBH4 (0.999) was then added by portions and the mixture was stirred at the same temperature for 1 hour. The reaction was quenched by addition of acetone (10ml) and the solvent was removed under reduced pressure. The residue was dissolved in CH2CI2, washed with water and then with brine and dried over Na2S04. After ~J..pC/ld~iull of the solvent, the orange oil gave on trituration from a hot mixture of diethyl ether/cy~,~ul~Aa,,_ an orange powder which was recrystallised from diethyl ~tlll~ llLdll~ to afford the title compound as a pale yellow solid (5.159) c~"t:~,U~l, ii"g to an authentic sample of Il llc~ iidLt: 68.
,llle~iidl~ 73 (1R.3R~-Methvl 1,2,3,4-tetrahvdro-2-ulllo~uau~ l (3.4-methvlenedioxvphenvl)-9H-Pvrido~3.4-blindole-3-carboxvlate Method A
To a stirred solution of IllL_lllle: iidlt~ 72 (9.79) and NaHC03 (2.799) in anhydrous CHCi3 (200ml) was added dropwise clllc,uactlyl chloride (5.3ml) at 0C under N2. The resulting mixture was stirred for 1 hour at the same temperature and diluted with CHCI3 (100ml). Water (100ml) was then added dropwise with stirring to the mixture, followed by a saturated aqueous solution of NaHCO3. The organic layer was washed with water until neutrality and dried over Na2SO4. After evaporation of the solvent under reduced pressure, the oily compound obtained was crystallised from ether to give the title compound as a pale yellow solid (9.959).
mp: 233C
[aLID20 = -125.4 (c = 1.17, CHC13).

Method B

1~ wo 95119978 2 ~ 8 13 ~ 7 F ~ o.s Chlu,vact:~yl chloride (4ml) was added dropwide to a solution of l"~e""e~ 72 (16.15) and triethylamine (7ml) in anhydrous CH2CI2 (20ûml) at 0C under N2.
The solution was stirred at ClC for 30 minutes, then diluted with CH2CI2 (300ml). The solution was washed with water (200ml), a saturated aqueous solution of NaHCO3 (300ml) ar~d brine (400ml). After drying over Na2SO4 and evaporation under reduced pressure, the resulting solid was washed with ether (300ml) to give the title comDound as a pale yellow solid (18.39).
Il l~l l l l~.~idL~ 74 Methvl 1,2,3.~tetrahvdro-6-me~hvl-1-(3,4-methvlenediùAvDhenvl)-9H-Dvrido~3.4-blindole-3-carboxvlate. cis and trans isomers The cis and trans isomers o~ the title compound were prepared using the method described in Il l~ did~; 1 but starting from racemic 5-methyl-tryptophan meth~JI ester and piperonal.
Cis isomer: yellow solid m.p.: 35C.
Trans isomer: yellow solid m.p.: 185C.
1"l~l " ,e~id~t:s 75 and 76 (1R, 3R)-Methvl 1,2,3,4-tetrahvdro-1-(7-(4-methvl-3~4-dihvdro-2H-benzo~1 .410xazirlvl)~-9H-~vrido~3.4-blindole-3-carboxvlate. cis isomer and (1S,3R)-Methvl 1.2,3.4-tetrahvdro-1-(7-(4-methvl-3.4-dihvdro-2H-benzo~1 .410xazinvl))-9H-pvrido~3.4-blindole-3~d, L~xv.dlt:. trans isomer The same method, as describ~d for illlt:lllw~iales 54 and 55, but starting from D-tryptophan methyl ester arld 4-methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-cdluu~dldellyde gave l"L~""edidl~ 75 the cis isomer as an oily compound 1H
NMR (CDCI3) ~ (ppm): 7.6-7.1 (m, 5H); 6.9-6.6 (m, 3H); 5.15 (br s, 1 H); 4.3 (t,2H); 4 (dd, 1 H); 3.8 (s, 3H); 3.3 (t, 2H); 3.3-2.95 (m, 2H); 2.9 (s, 3H); 1.6 (br s) and i"~""e-lidL~ 76, the trans isomer as white crystals m.p.: 119-121C.
3û l"~t~""edidL~ 77 Methvl 1.2.3.4-tetrahvdro-1-(5-(N-benzvlindolinvl))9H-Dvrido~3.4-blindole-3-carboxvlate, mixture of (1R. 3R) and (1S. 3R) isomers The same method, as described for i"~""ediclL~,s 54 and 55, but starting from D-tryptophan methyl ester and N-benzylindoline-5~d~ bu~dld~l ,yde gave i"Le:""edi ~ 77 as an oily ~pound.

~3~377 WO 95119978 ~ P~ ~ 7a.'~ ~ io~

lledidI~s 78 and 79 (1 R. 3R)-Methvl 1 .2.3.4-tetrahvdro-1 -(4~d, uu, ~ 1 ,u,~YPhenvl)-9H-PYrido~3.4-blindole-3-carboxvlate. cis isomer and (1 S. 3R)-methvl 1.2.3 4-tetrahvdro-1-(4-w,I,u,I~ ,o~/phenvl)-9H-pvrido~3 4-blindole-3-carboxvlate. trans isomer The same method, as described for i"~c:""ecl;~ 54 and 55, but startin3 from D-tryptophan methyl ester and methyl 4-fommylbenzoate gave 1" ", 78, the cis isomer as white crystals m.p.: 1 57-160C and ll l ~lladidl~ 79, the trans isomer as pale yellow crystals m.p.: 124-126C.
I"l~""a.lidLe 80 (1R. 3R)-Methvl 1.2.3 4-tetrahvdro-2-~2-(benzvloxYcarbonvl)-R-Prolvl1-1-(3 4-methvlenedioxvphenvl)-9H-pvrido~3 4-blindole-3-cd,~uj~latc A solution of N-(benzyloxycarbonyl)-D-proline acid chloride (0.64 9, 2.4 mmol) in anhydrous di~l,lolu",~ll,d"e (10 mL) was added dropwiseto a stirred solution of i" ",e,did~t: 54 (0.7 9, 2 mmol) and triethylamine (0.33 mL 2.4 mmol) in ~iul,lu,u",~Il,d"e (15 mL) at - 10C. The mixture was stirred for 2 h at - 10C
after which it was diluted with ~i.l,lu,u,,,~ll,dne (50 mL) washed with hydrochloric acid (1 N), water, a saturated solution of NaHCO3, a saturated NaCIsolution and dried over Na2SO4. Evaporation of the solvent and recry of the crude product from methanol gave the title cPmDound as pale yellow crystals (0.75 9) m.p.: 268-270C
I~ a~lid~ 81 ~1 R. 3R)-Methvl 1.2 3 4-tetrahvdro-2-~2-(benzvloxvcarbonvl)-S-Prolvl1-1-(3 4-methvlenedioxvphenvl)-9H-pvrido~3 4-blindole-3-cd, uo,.vlatc A solution of N-(benzyloxycarbonyl)-L-proline acid chloride (0.86 9, 3.2 mmol) in anhydrous di. I ~lu~ u~ a~e (10 mL) was added dropwise to a stirred solution of ill~lllladidltl 54 (0.91 9 2.6 mmol) and triethylamine (0.44 mL 3.2 mmol) in di. l ,Ir,, u" ,t:~i Idl ,e (20 mL) at - 1 0C . The mixture was stirred for 2 hours at - 1 0C
after which it was diluted with ~iH,Iu,u,,,~l,d,,e (60 mL), washed with IlJ~IU~.III~rjC acid (1N), water, a saturated solution of NaHC03, a saturated NsCI solu~i~n and dried over NatSO~ EYaporation o~ thtt stlvent snd WO95/19978 ~1813~ r~ ooi~
recrys , of the crude product from methanol/water gave the title compound as pale yellow crystal!; (0.8 9) m.p.: 115-120C.
I~ l, 82 (1R. 3R)-Methvl 1.2.3.4-tetrahvd~o-2-(2-~ lUl.lu"iu,Iv1)-1-(3 4-methvl~"~ iiu,~phenvl)-9H-Pvridt~r3.4-blindole-3-t d~ L U,~Y:
To a soiution of (S)-(-)-2~illul~,lul iullic acid (87 ul 1 mmol) in anhydrous tii.l,lu,u"":~l,a"e (15 mL) was added dic~lul.. xyl~dlL "ide (0.23 9 1.1 mmol). I"hr",e~iidlt: 54 (0 35 9 1 mmol) was then added and the mixture was stirred at room ~t:" ,..~ re for 20 hours. The formed ~I ~ui~itdlt: of dicyclohexylurea was removed by filtration the filtrate was evaporated in vacuo and the cnude product was plJrified by flash ~IIIu~ d~ eluting with toluene/ethyl acetate: 95/5. The oily compound obtained was then crystallised from ~ dll~ to give the ti~'le compound as pale yellow crystals (0.31 9) m.p.: 125-127C.
. l l . 83 (1 R. 3R)-Methvl 1 .2.3.4-tetrahvdro-2-(2~1,1t"uu,u"itj"~1)-1-(3 4-methvl~. 16 iiu~ t~ /I)-9H-Pvrid~r3.4-blindole-3-, d, UUA~
To a solution of (R)-(+)-2-~ ,u~,,upioni~ acid (191 ul 2.2 mmol) in anhydrous ii~l,ltj,u,,,t~Ll,d,,e (30 mL) was added dicyul~l,t-xjl~ dlL ,lid~ (0.45 9 2.2. mol). Ill ",- 54 (0 7 9 2 mmol) was then added and the mixture was stirred at room temperature for 20 hours. The formed ~ ui~ild~t: of dicyclohexylurea was removed by filtration the filtrate was evaporated in vacuo and the cnude product was pl~rified by flash ~.lllullldtuyld~Jlly eluting with toluene/ethyl acetate: 95/5. The oily compound obtained was then, ,y from ~tl,~,A,~Ad"e to give the ti:le comPound as pale yellow crystals (0.74 9) m.p. :126-128C.
.

11l 1116 iidLt:a 84 and 85 - (1R. 3R)-Methvl 1.2.3.4-tetrahvdro-1-(3.4- iiLt:"~/lu,~vPhenvl)-9H-pvrido~34-blindole-3-cd, L,u ~ tc cis isomer and (1 S. 3R)-methvl 1 .2.3.4-tetrahvdro-1-(3 4-dibenzvloxvPhenvl)-9H-Pvrido ~3 4-blindole-3-cd~6uA~ tc trans isomer WO95119978 ~ 'i' I "? ~ F~.I/I!I~'.'C IOJ

The same method as described for i"t~""edidl~s 54 and 55 but starting from D-tryptophan methyl ester and 3,4-dibenzyloxyb~"~dl~e~,yde gave illl~ di 84, the cis isomer as an oily compound 1 H NMR (CDCI3) ~(ppm): 7.5 - 6.95 (m, 15H); 6.85 (s, 1H); 6.75 (s, 2H); 5.1 (s, 2H); 5 (br s, 1H); 4.95 (d, 2H) 3.85 (dd, 1H); 3.7 (s, 3H); 3.2-2.8 (m, 2H); 2.3 (br s, 1H) and illL~llllel.lidle~ 85, the trans isomer as an oily compound 1HNMR (CDCI3) ~ (ppm) 7.6-7 (m, 15H); 6.9-6.7 (m, 3H); 5.2 (br s, 1H); 5.1 (s, 2H); 5 (s, 2H); 3.8 (t, 1H); 3.65 (s, 3H);
3.3-3 (m, 2H); 2.25 (br s, 1 H).
1 0 11 IL~I 11 lI~ idlt: 86 (6R. 12aR)-2,3,6.7.12.12a-Hexahvdro-6-l3.4-dibenzvloxvDhenvl)-2-methvl-~vrazinor2'. 1': 6.11Pvrido~3,4-blindole-1,4-dione The same two step procedure but starting from ill~,.llltldid~t~ 84 and methylamine gave, after recr, ' " ' ~ from di~ lulllt~ d~ , the title compound as white crystals m.p.: 158-160C, [a]2~D = + 11.7 (c = 1.23;
CHCI3).
I,.t~.",~didle 87 Methvl 1,2,3,4-tetrahvdro-1-(5-r2-methv'i~Gi" ' ~ 1))-9H-Pvrido~3,4-blindole-3-Cd,~uA~: ' . mixture of (1R.3R) and (1S.3R) isomers The same method, as described for i"' ". ' ' 54 and 55, but starting from D-tryptophan methyl ester and N-methyli~.ui,, ' ' ,~5~d, L,u,~al,l~l ,yde gave illl~:llllt:didl~ 87 as an oily compound.
ExamPle 1 Cis-2.3.6.7.12.12a-hexahvdro-2-methvl-6-(3.4-~ e-liù~,,l,t"vl)-Dvrazinor2'. 1':6.1 lPvrido~3.4-blindole -1 .4-dione a) To a stirred solution of i"te:l"n:u', ,~1 (2 9) and NaHC03 (0.6 9) in anhydrous CHCI3 (40 mL) was added dropwise ul~ uac~t~l chloride (1.1 mL) at 0C.
The resulting mixture was stirred for 1 hour at the same temperature and diluted with CHCI3. Water (20 mL) was then added dropwise with stirring to the mixture, followed by a saturated solution of NaHCO3. The organic layer was washed with water until neutrality and dried over Na2SO4. After . 35 U~ 01d~iOI~ of the solvent under reduced pressure, cis-methvl 1.2.3.4-WO95/19978 2~377 tetrahydro-2-1,1 llul uac~ .4-methvlel~edio,~vphenvl)-9H-Pvridor3.4-blindole-3~d,L,u,~ , was obtained as an oil which was crystallised from ether (2 9, m.p.: 215-218C) and was used without funther purification in the next step.

b)To a stinred suspension of l:he l,I~lu~uac-:tyl i"'~.", ' (û.34 9) in MeOH
(20 mL) was added at ambierlt temperature a solution of methylamine (33% in EtOH) (0.37 mL) and the resulting mixture was heated at 50C under N2 for 14 hours. The solvent was removed under reduced pressure and the residue 1 û was dissolved in CH2CI2 (50 mL). After washing with water (3x30 mL), drying over Na2SO4 and evaporatinlg to drYness, the residue was purified by flash .,11ll ' ~ d~lly eluting with CH2C12/MeOH (99/1) and recrystallised from MeOH to give the title comPound as white crystals (0.19 9) m.p.: 253-255C.
Analysis for C22H1gN3O4 C~l~lIlAtPr~ C,67.86;H,4.92;N,10.79;
Found:C,67.53;H,4.99;N,10.62%.
The following compounds were ~btained in a similar manner:
ExamPle 2 Cis-2. 3. 6. 7.12.12a-hexahvdro-2-butvl-10-fluoro-6-(4-methoxYPhenvl)-Pvrazinor2'. 1 ' 6.11Pyrido r3.4-blindole-1 .4-dione The same two step procedure but stanting from butylamine and i"t~"" " ' 52 gave, after recrY~' " ", fronn ethanol, the title comPound as white crystals m.p. : 182C.
Analysis for C2sl 1~6r~3O3 (0.1 H2O):
C~ C,68.67;H,6.û4;N,9.61;
Found:C,68.38;H,6.11 ;N,9.53%.
ExamPle 3 Trans-2.3.6.7.12.12a-hexahvdrr~-2-methvl-6-(3.4-methvl~ dio,~vPhenvl)- PYraZinor2~ 1':6.1 lPvridor3.4-blindole -1 .4-dione -WO95/19978 2~813~7;,, P~ 7~ 83 The same two step procedure but starting from methylamine and i~ . ",e~idLt: 2 save, after recry " 'ic:l from toluene, the title comDound as white crystals m.p.: 301-303C.
Analysis for C22H1 gN304 C~lr~' ' C,67.86;H,4.92;N,10.79;
Found:C,67.98;H,4.98;N,10.73%.
ExamDle 4 cis-2~3~6~7~12~12a-hexahvdro-6-(3~4-methvlenedioxvDhenvl) Dvrazino~2'. 1':6.1 lDvrido~3.4-blindole -1 .4-dione The same two step procedure but starting from ammonia and i"~,.", " ~ 1 gave, after recry ' " " ~ from methanol, the title comDound as white crystals m.p.: 283-285C.
Analysis for C21 H1 7N304 C~lr~' ' ' C,67.19;H,4.56;N,11.19;
Found:C,67.04;H,4.49;N,1 1 .10%.
ExamDle 5 Cis-2.3.6.7.12.12a-hexahvdro-10-fluoro-6-(4-methoxvPhenvl)-2-(2~2~2 trifluoroethvl)-Dvrazino~2' . 1 ': 6. 1 1Pvrido ~3.4blindole-1 .4~ione The same two step procedure but starting from 2,2,2-trifluoroethylamine and i"'~.",e~idl~ 52 gave, after recry ' " , from ethanol/diisopropyl ether, the title comDound as white crystals m.p.: 1 90C.
Analysis for C23H1 gF4N303:
C~lr,ll' ' ~: C, 59.87; H, 4.15; N, 9.11;
Found:C,59.81 ;H,4.18;N,9.21%.
ExamDle 6 Cis-2.3.6.7. 12.1 2a-hexahvdro-1 O-fluoro-2-methvl-6-(3.4-methvlenedioxvDhenvl)-Dvrazino~2', 1 ': 6. 1 lDvrido~3.4-blindole-1 .4-dione The sama two step procedure but starting from methylamine and ill~ didLt:
50 gave, after recry~ ' " , from ethanol, the title comDound as white crystals m.p.: 292C.
Analysis for C22H1 gFN3O4 35 C:~lr,ll' ' ~: C, 64.86; H, 4.45; N, 10.31;

W0 95/19978 ~ ~ 8 ~ 3 7 ~ r~ 7~

Found: C, 64.66; H, 4.60; N, 1~).21%.
Example 7 (6R, 1 2aS)-2.3,6.7. 12.1 2a-l le~Adl I t'dl u-2-methvl-6-(3.4-methvl~:~ lediUAY'P~ l IVI) Pvrazinor2' . 1 ': 6. 1 lpvrido~3.4-blirldole-1 ,4-djone The same two step procedure but starting from methylamine and the trans isomer of illLe~ didl~ 56 gav~, after recry ' " ' ) from toluene, the title comPound as white crystals m.p. :287-289C.
Analysis for C22H1 gN304 (0.25 toluene):
CAI^II' J: C, 69.16; H, 5.13; I~l, 10.19;
Found:C,69.09;H,5.14;N,10.19%.

[a]D =-293.4 (C=1.28; CHC13).
ExamPle 8 (6S, 1 2aR)-2.3.6.7. 12.1 2a-hexa~lvdro-2-methvl-6-(3.4-methvlenedioxvPhenVI)-PVrazinO ~2', 1': 6.11pvrido~3,4-blindole-1,4-dione The same two step procedure t)ut starting from methylamine and ill~t:lllleUldL~
55 gave, after recry~ " ~ frDm toluene, the title comPound as white crystals m.p.: 287C.
Analysis for C22H1 gN3O4 (0.3 toluene):
CPI.^,III~ C, 69.41; H, 5.17; N, 10.08;
Found: C, 69.56; H,5.24; N, 1~.08%.

[a]D = 1 297 9 (C=1.21; CHC13).
ExamPle 9 Cis-2. 3. 6. 7. 12.12a-hexahvdro-2-r2-(2-Pvridvl)-ethvll-6-(3.4-iuA~ l l ;l)-pvrazinr~2~ -6~1 lpvrido~3 ~4-blindole-1 ~4-dione The same two step procedure! but starting from 2-(2-pyridyl)ethylamine and illtelllle~idlt~ 1 gave, after recr~: ' ' ' , from 2-propanol, the title comPound as white crystals m.p.: 218-222''C.
Analysis for C28H24N44:
CAIrll' ': C, 69.99; H, 5.03; N, 11.66;
Found: C, 69.92; H, 5.16; N, 11.48%.
-WO 95/19978 ~ 1 81~ 7!7~. ~, P~ 183 Example 1 0 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-(2-Dvridvlmethvl)-6-(3,4-methvlt" ,~ioA~phenvl)-pvrazinor2', 1 ': 6.1 lPvrido~3.4-blindole-1 ,4-dione The same two step procedure but starting from 2-pyridylmethylamine and il~t~.lll~didL~ 1 gave, after recry ' " " ~ from DMF/water, the title compound as ueam crystals m.p: 285-286C.
Analysis for C27H22N4o4 (0 4 H2O):
C~lc~ t~d: C, 68.46; H,4.85; N, 11.83;
Found: C, 68.58; H, 4.88; N, 11.90%.
ExamDle 1 1 Cis-2,3.6,7. 12,1 2a-hexahvdro-2-(3-pvridvlmethvl)-6-(3.4-methvl~i, ,e.liuAyphenvl)-Pvrazinor2~ 1 ': 6.1 lPvridor3~4-blindole-1 ,4-dione The same two step procedure but starting from 3-pyridylmethylamine and ill' 111-' 1 gave, after recry~L~ 'io" from CH2C12/MeOH, the title compound as cream crystals m.p.: 292-293C.
Analysis: C27H22N44 C~ t~d: C, 69.52; H, 4.75; N, 12.01;
Found: C, 69.27; H, 4.74; N, 11.37%.
r_xamPle 12 Cis-2.3.6.7.12.12a-hexahvdro-2-(4-Pvridvlmethvl)~-(3~4-" ~.,;h~ e~ioA~,,I ,~"~I)-Pvrazinor2'. 1 ': 6.11pvridor3.4-blindole-1 .4-dione The same two step procedure but starting from 4-pyridylmethylamine and i" Ill~didLt: 1 gave, after recr~ " , from MeOH, the title compound as pale yellow uystals m.p.: 273-274~C.
Analysis for C27H22N4o4 (1 8 H2O):
CAI~ ^; C, 65.00; H, 5.17; N, 11.23;
Found: C, 65.11; H, 4.85; N, 11.07%.
Example 13 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-ethvl-6-(3.4-methvlenedioAYPhenvl) Pvrazinor2' .1':6.1 lPvridor3~4-blindole -1 .4-dione .
.

~ W095/19978 ~ 3 1377 ~ ~/cciOs The same two step procedure t)ut starting from ethylamine and illi~ id~
3ave, after recrys " ' , from methanol, the title compound as white crystals m.p.: 272-274C.
Analysis for C23H21 N304 CAI~ I C,68.47;H,5.25;N,10.42;
Found:C,68.52;H,5.35;N,10.53%.
ExamDle 14 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-(2.2.2-trifluoroethvl)-6-(3.4-1 1 I~ "~h,. ,ediuAvphenvl)-Pvrazinor2~ 1':6,1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from 2,2,2-trifl~u,u_;~.,fl...,,i,,e and i"~",. " 1 gave, after ,.~ from EtOH, the title compound as white crystals m.p.: 303C.
Analysis for C23H1 8F3N34 CAlr.ll~At~l C,60.40;H,3.97;N,9.~9;
Found:C,60.43;H,4.1 5;N,9.16%.
ExamPle 15 Cis-2.3.6.7. 12,1 2a-hexahvdro-6-(3.4-methvlt:"t:diuAvPhenYl)-2-pr Pvrazinor2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The same hvo step procedure but starting from propylamine and i" ", " ' gave, after recry~ from methanol, the title comPound as white crystals m.p.: 270-271C.
Analysis for C24H23N3O4:
CAIr:~' ' C,69.05;H,5.55;N,10.07;
Found:C,69.22;H,5.50;N,9.80%.
Example 16 Cis-2.3.6.7.12.12a-hexahvdro-2-isoPropyl-6-(3~4-lll~;h~ diùA~phenyl) pyrazinor2', 1':6.1 lPYridor3~4-blindole -1 .4-dione The same two step procedure b~lt starting from isopropylamine and i"lc:"~ - "
1 gave, after recry~ " ", from methanol, the title compound as ~vhite crystals m.p.: 248-250C.
Analysis for C24H23N3O4:
. 35 C~ ' ' C,69.05;H,5.55;N,10.07;

WO 95/19g78 ~ 3 7 7 r~ 75~'C ~1O.~ --Found:C,68.86;H,5 66;N,10.21%.
ExamPle 17 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-cvcloPropvl-6-(3~4-methv~ di~Avphenvl) Dvrazino~2.1':6.1lDvrido~3.4-blindole-1.4-dione The same t~,vo step procedure but starting from cyclopropylamine and il l' Ill~didle 1 gave, sfter recry ~ from methanol, the title comDound as vlhite crystals m.p.: 290-292C.
Analysis for C24H21 N304:
10 CAlr~lAt-r~ C,69.39;H,5.10;N,10.11;
Found:C,69.1 1 ;H,5.20;N,9.94%.
ExamDle 18 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-butvl-6-(3.4-methvl~ ,liuA~Dhenvl)-Dvrazino~2'.1':6.1lPvridor3.4-blindole-1.4-dione The same two step procedure but starting from butylamine and i" ~ ;dl~ 1 gave, after recr~ I from ,,,~ll,d,,ùlJ~_ , the title comDound as white crystals m.p.: 241-243C.
Analysis for C2sH2sN3O4:
CAIr~ tPrl C,69.59;H,5.84;N,9.74;
Found:C,69.77;H,5.82;N,9.81 %.
ExamPle 1 9 Trans-2.3.6.7.12.12a-hexahYdro-2-butvl-6-(3~4-methvl~)eJiuA~Dhenvl) Dvrazino~2'.1':6.1lDvrido~3.4-blindole-1,4-dione The same hvo step procedure but starting from butylamine and i" ~ idt~ 2 gave, after recr~. , from toluene, the title comPound as white crystals m.p.: 243C.
Analysis for C2sH2sN3O4:
CAlrl ~ C,69. 59; H, 5. 84; N, 9. 74;
Found:C,69.80;H,5.78;N,9.52%.
ExamDle 20 Cis-2.3.6.7 .12.1 2a-hexahvdro-2-cvcloDropvlmethvl-6-(3,4-35 methv~ ediu~Phenvl)-pvrazino~2~ :6.1lDvrido~3~4-blindole-1.4-dione ~ W0 9S119978 ~ ~ 8 1 3 7 7 P~ o~

The same two step procedure but starting from cyclopropylmethylamine and ill' IlledidLt: 1 gave, after recry~' " " , from methanol, the title comPound as white crystals m.p.: 217-218C.
Analysis for C2sH23N3O4:
C~lr~ t~l C,69.92;H,5.40;N,9.,78;
Found:C,70.02;H,5.47;N,9.84%.
ExamPle 21 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-cvcloPentvl-6-(3.4-methvlenedioxvPhenvl) Pvrazinor2'. 1':6,1 lPvridor3.4-blindole -1 .4~ione The same two step proced~re but starting from cyclopentylamine and i"'~,""edidL~ 1 gave, after recry~ from acetone, the title comPound as white crystals m.p.: 270C.
Analysis for C26H2sN3O4:
15 C~ t~ C,70.41;H,5.68;N,9.~7;
Found:C,70.58;H,5.63;N,9.38%.
ExamPle 22 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-cvclohexvl-6-(3.4-methvlenedioxvPhenvl)-Pvrazino~2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from cyclohexylamine and illte:llll~didl~: 1 gave, after recry;.Ldllisdliu" from methanollwater, the title comPound as white crystals m.p.: 268-269C.
Analysis for C27H27N34 CAlr~ tP~ C,70.88;H,5.95;N,9.~8;
Found:C,70.82;H,5.89;N,9.21 %.
ExamPle 23 Cis-2.3.6.7.12.12a-hexahvdro-2-benzvl-6-(3.4-methvl~"e~io,~ vl~-Pvræino~2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The sam3 two step procedure blJt starting from benzylamine and i"lt~
gave, after recry ' " , frorrl u'i.,l,lu,u",~il,d"~ "e, the title compound as white crystals m.p.: 285-287C.
Analysis for C28H23N3o4(1 H2O):
C~ lI It~-1 C,69.55;H,5.21;N,8.69;

WO 95/19978 ~ 1 8 1`~ 7 ~

Found:C,69.30;H,5.06;N,8.48%.
ExamPle 24 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-(4-fluorobenzvl)-6-(3.4-methvlenedioxvPhenvl)-Pvrazinor2'. 1':6.1 lPvridor3.4-blindole -1 ,4-dione The same two step procedure but starting from 4-fluorobenzylamine and ill' Illedidte 1 gave, after ,t:-,,y~' " ' , from acetone, the title comPound aswhite crystals m.p.: 281-283C.
Analysis for C2gH22FN3O4:
CAI~II' ' C,69.56;H,4.59;F,3.93;N,8.69;
Found:C69.54;H,4.58;F,3.82;N,8.63%.
ExamPle 25 Cis-2.3.6.7. 12,1 2a-hexahvdro~-(4-methoxvphenvl)-2-methvl-Pvrazinor2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from methylamine and il~t~llledid~e 3 ~ave, after recry' " " ~ from 2-propanol, the title comPound as v,lhite crystals m.p.: 257-263C.
Analysis for C22H21 N303:
CA~ Ate~I C,70.38;H,5.64;N,11.19;
Found:C,70.11;H,5.55;N,11.15%.
ExamPle 26 Trans-2.3.6.7.12.12a-hexahvdro-6-(4-methoxvPhenvl)-2-meth Pvrazinor2'.1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from methylamine and i, l~el 1 l ledidle 4 gave, after recry " " , from di;~.u,ulu~.yl ether, the title compound as v,thitecrystals m.p.: 225-228C.
Analysis for C22H21 N303 CAIC'I' ' C,70.38;H,5.64;N,11.19;
Found:C,70.34;H,5.77;N,11.19%.
ExamPle 27 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-ethvl-6-(4-methoxvPhenvl)-35 Pvrazinor2'.1':6.1lPvridor3.4-blindole-1.4-dione W0 9~i119978 41 P~ 7~ o~
The same two step procedure l~ut starting from ethylamine and i"~""a.lidl~ 3 gave, after recrj ' " " , from methanol, the title comPound as v,lhite crystals m.p.: 245-255C.
Analysis for C23H23N33 C~lr~latP~I C,70.93;H,5.95;N,10.79;
Found:C,70.74;H,6.06;N,10.87~D.
ExamPle 28 Cis-2,3,6,7~12 12a-hexahvdro-6-(4-",~l,IU~YP~ 1)-2-(2,2,2-trifluoroethvl)pvrazinor2', 1':6.1 lovridor3.4-blindole -1 .4-dione The same two step procedure but starting from 2,2,2-trifluoroethylamine and i"l~""e~ 3 gave, after ,~,,y ' " " ~ from ethanol, the title compound as v~hite crystals m.p.: 232C.
Analysis for C~JH20r3~ 03:
Ca~ t~ C,62.30;H,4.55;N,9.48;
Found:C,62.08;H,4.66;N,9.54%.
ExamPle 29 Cis-2.3.6.7. 12.1 2a-hexahYdro-2-butvl-6-(4-methoxYPhenvl) Pvrazinor2'.1':6.11Pvridor3.4-blindole-1.4-dione The same two step procedure l~ut starting from butylamine and i"~"" ' ' 3 gave, after recrys' " ' , from methanol,the title comPound as v,/hite crystals m.p.: 157C.
Analysis for C2sH27N3o3(o 5H2o) CAI~ 1 C,70.40;H,6.62;N,9.85;
Found:C,70.25;H,6.60;N,9.83%.
ExamPle 30 Trans-2.3.6.7. 12.1 2a-hexahvdro-2-butvi-6-(4-methoxYPhenvl)-Pvrazinor2'. 1':6.1 lPvridor3.4-blinldole -1 .4-dione The same two step procedure but starting from butylamine and i"t~""- ' 4 gave, after recr~ from methanol, the title compound as v~hite crystals m.p.: 212-214C.
Analysis for C25H27N33 . 35 Cal~ C,71.92;H,6.52;N,10.06;
.

WO 95/19978 ~ P~

Found:C,71.81;H,6.55;N,10.03%.
r_xamPle 31 Cis-2.3.6.7. 12.1 2a-hexahvdro-6-(4-" ,~I"u,~ I)e"~1)-2-cvcloProPvimethvl-Pvrazinor2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from cyclopropylmethylamine and illl~llll~didl~ 3 gave, after recr~ " " , from methanol, the title comPound as whlte crystals m.p. :180-185C.
Analysis for C2sH2sN3O3 (0-5H20):
CAIC~ t.~ C,70.74;H,6.17;N,9.90;
Found:C, 70.91; H, 6.16; N, 9.80%.
ExamPle 32 Cis-2.3.6.7. 12.1 2a-h~,~dl, id~ u-2-benzvl-6-(4-methoxvPhenvl)-PVrazinO~2'.1':6.1 lPvridor3.4-blindole -1 .4-dlone The same two step procedure but startins from benzylamine and i" ", " ' 3 gave, after recry~ from acetone, the title comPound as whlte crystals m.p.: 275-279C.
Analysis for C2gH2sN3O3:
C~ t~ C,74.48;H,5.58;N,9.31;
Found:C,74.53;H,5.60;N,9.20%.
r_xamPle 33 Cis-2.3.6.7.12.12a-hexahvdro-6-(3-"~ ù,~ "vl)-2-methvl-PVrazinor2'. 1':6.1 lPvridor3~4-blindole -1 .Wlone The same t~Yo step procedure but startlng from methylamine and i"'~.", ' 5 gaYe, after recry " " ~ from methanol, the title comPound as white crystals m.p.: 267-269C.
Analysis for C22H21 N303 C~ ' ' ' C,70.38;H,5.64;N,11.19;
Found:C,70.32;H,5.59;N,1 1 .25%.
Example 34 Cis-2.3.6.7.12.12a-hexahvdro-6 (~ cl:~u,~ "~1)-2-methvl-Pvrazinor2~ :6.1lpvridor3~4-blindole-1.4-dione O WO 95119978 ' r ~ ~
The same two step procedure bl~t starting from methylamine and i"l~""edid~ 6 gave, aft~r recr~: " " , from methanol, the title comPound as white crystals m.p.: 247-248C.
Analysis for C23H23N33 CAICI II ~t~l' C,70.93.H,5.95;N,10.79;
Found:C,71 .23;H,5.95;N,10.63%.
ExamPle 35 Cis-2.3.6.7. 12.1 2a-hexahvdro-6-(4-ethoxYPhenvl)-2-cvcloPropvlmeth Pvrazino~2', 1':6,1 lPvrido~3.4-blindole -1 .4-dlione The same two step procedure but starting from cyclopropylmethylamine and ,"~edid~e: 6 gave, after recr~ from 2-propanol, the title comPound as white crystals m.p.: 160-162'C.
Analysis for C26H27N33 CAIclllAtF!rl C,72.71;H,6.34;N,9.78;
Found:C,72.28;H,6.39;N,9.71 %.
ExamPle 36 Cis-2.3.6.7. 12.1 2a-h~dl . ~ u-6-(2.3-dihvdl uur, ,~urblfuran-5-vl)-2-methvl-PVrazino~2'.1':6,1 lPYridor3.4-blin~ole -1 .4-dione The same two step procedure b~Jt starting from methylamine and i"~"" ' ' 8 gave, after recr~ " ~ from methanol, the title comPound as white crystals m.p.: 292-294C.
Analysis for C23H21 N303:
CA~r~' ' ' C,71.30;H,5.46;N,10.85;
Found:C,71 .15;H,5.56;N,10.84%.
ExamPle 37 Cis-2.3,6,7,12,12a-hexahydro~-(2.3-dihvd,ub~"~u~blfuran-5-vl)-2-cvcloProPvlmethvl-Pvrazino~2~ 1':6.1 lPvrido~3.4~lindole -1 ,4-dione The same two step procedure but starting from cyclopropylmethylamine and i"' I"e,iidL~ 8 gave, after recry, ' ~ n from methanol, the title compound as white crystals m.p.: 165-166C.
Analysis for C26H2sN3O3:
35 CA~r`l' ' ' C,73.05;H,5.89;N,9.133;

WO 95/19978 Z ~ 7.~; r~"~;l 7~ o.
Found:C,73.08;H,5.97;N,9.87%.
ExamPle 38 Cis-2.3.6.7. 12.1 2a-hexahvdro-6-(3.4-eth~lel-eJiuAvPhenvl)-2-methvl-PVrazino~2'.1':6,1lPvrido~3.4-blindole-1.4-dione The same two step procedure but starting from methylamine and i" 1,, " ' 10 gave, after recr,r~ ' " , from acetone, the title comPound as white crystals m.p.: 303-305C.
Analysis for C23H21 N304 C~lc~ tP~I C,68.47;H,5.25;N,10.42;
Found:C,68.35;H,5.31 ;N,10.27%.
Example 39 Cis-2.3.6.7. 12.1 2a-hexahvdro-6-(3.4-eth~l~l ,t7.ii~AvPhenvl)-2-cvclopropvlmethvl-PVrazino~2',1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from cyclopropylmethylamine and i"t~," "e~iclc: 10 gave, after recry~l..::;_ :iu" from ~i.,l llc,l u" l~ dl l~ ;1, the title comPound as white crystals m.p.: 288-290C.
Analysis for C26H25N34 C~lrl IlAt~-l C,70.41 ;H,5.68;N,9.47;
Found:C,70.1 5;H,5.62;N,9.30%.
ExamPle 40 Cis-2,3,6,7. 12.1 2a-hexahvdro-2-butvl-6-(2~1 llu, uul~
PVrazino~2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from butylamine and i" ",~ 12 gave, after recr~ from methanol/water, the title compound as white crystals m.p. :146C.
Analysis for C24H24CIN3O2(0.75 H2O):
C~lr~ C,66.20;H,5.90;N,9.65;
Found:C,66.1 5;H,5.95;N,9.69%.
ExamPle 41 Cis-2.3.6.7.12.12a-heAdl,~J,u-6-(4-~l,lu,u,,l,~"~rl)-2-methvl-Pvrazino~2'.1':6.1lPvrido~3.4-blindole-1.4-dione -O WO95/19978 21gii377 r~llr~

The same two step proce~ure but starting from methylamine and ' ' 13 gave, after recr~s' " :l from methanol, the title compound as white crystals m.p.: 274C.
Analysis for C21 H1 8CIN32 (0 ~5 H2O):
CAlr~' ' C,65.63;H,4.85;N,10.93;
Found:C,65.39;H,4.84;N, 1 0.85%.
ExamPle 42 Cis-2,3,6,7,12~12a-hexahvdro-2-butvl-6-(4--:~11u,u~l,~,,~l)-Pvrazinor2'. 1':6.1 lDvrido~3.4-blinclole -1 ,4-dione The same two step procedure bLJt starting from butylamine and i"~""e, idLc: 13 gave, after recry, ' " 1 from ethanol/water, the title compound as white crystals m.p.: 164-1 66C.
Analysis for C24H24CIN3O2:
~ A~ ltf-tl C,68.32;H,5.73;C1,8.~0;N,9.96;
Found:C,68.48;H,5.64;CI,8.37;N,~.99%.
Example 43 Cis-2,3,6,7,12,12a-hexahvdro-6-(3,4-diL,l llo uul ~ 1)-2-methvl-PVraZino~2', 1':6.1 lPvrido~3.4-blindole -1 .4-dione The same two step procecure but starting from methylamine and llo~didl~ 15 gave, after l~uly~L ~ clLiull from ethanol/DMF, the title compound as white crystals m.p.: ~260C.
Analysis for C21 H17CI2N32 ( 5 H2O):
CAIC' Il-'?C~ C,59.39;H,4.29;N,9.93;
Found:C,59.32;H,4.16;N,9.99%.
ExamPle 44 Cis-2.3.6.7.12.12a-hexahvdro-2-butvl~-Phenvl-pvrazino~2l~1l:6~1lpvrido~3~4 blindole-1,4-dione The same two step procedure but starting from butylamine and cis-methyl 1 ,2,3,4-tetrahydro-1 -phenyl-9H-p~rido[3,4-b]indole-3~d, ~u,~y' 1 gave, after recr~ from methanol/water, the title comPound as white crystals m.p.:
243-245C.
. 35 Analysis for C24H25N32 WO 95/19978 ~ ~ 8 ~ ~ ~ 7 ~ c loJ

C^~ C,74.39;H,6.50;N,10.84;
Found:C,74.54;H,6.51 ;N,1 0.86%.
1. D. Soerens et al., J. Org. Chem. 44, 535 - 545 (1979).
ExamPle 45 Cis-2.3.6.7. 12.1 2a-hexahYdro-2-benzvl4-Phenvl-pvrazinor2~ 6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from benzylamine and cis-methyl-1,2,3,4-tetrahydro-1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate gave, after recry~ " ~ from methanol, the title comPound as white crystals m.p.: 193-1 95C.
Analysis for C27H23N32 CA~^,II' ~. C,76.94;H,5.50;N,g.97;
Found:C,77.23;H,5.54;N,9.97%.
ExamPle 46 Trans-2.3.6.7. 12.1 2a-hexahvdro-2-benzvl4-Phenvl-pvrazinor2~ 6~1 lpvridor3~4 blindole -1 .4-dione The same two step procedure but starting from benzylamine and cis-methyl-1 ,2,3,4-tetrahydro-1 -phenyl9H-pyrido[3,4-b]indole-3-w, LJ~ '^ gave, after recry ' " " ~ from methanol, the title comPound as white crystals m.p.:
284C.
Analysis for C27H23N32 CAI^I II^'^'~ C,76.94;H,5.50;N,9.97;
Found:C,76.88;H,5.45;N,9.89%.
ExamPle 47 Cis-2.3.6.7.12.12a-hexahvdro-2-methvl4-(1 .2.3.4-tetrahvdro4-naPhthvl)-Pvrazinor2'.1':6.1lPvridor3.4blindole -1 ,4-dione The same two step procedure but starting from methylamine and i"'~,.",- ' 17 gave, after recry ' " ~ from methanol, the title compound aswhitecrystals m.p.:>260C.
Analysis for C25H25N32 CAIr~ t-rI C,75.16;H,6.31;N,10.52;
35 Found:C,74.93;H,6.43;N,10.63%.
.

W095/19978 ~8~3~7 - F~~ S~ lo~

ExamPle 48 Cis-2.3.6.7.12.12a-hexahvdro-2-isoPropvl-6-(1 .2.3.4-tetrahvdro-6-naPhthvl) PVrazino~2'. 1':6.1 lPvrido~3.4-blindole -1 .4-dione The same two step procedure but starting from isopropylamine and i"' Illedidle 17 gave, after recry~' "' " ~ from the ~itle comPound as off-white crystals m.p.: 244-246C.
Analysis for C27H2gN3o2 (0 25~20):
CAlr~' ' ' C,75.06;H,6.88;N,9.7'3;
Found:C,75.00;H,6.83;N,9.69%.
Example 49 Cis-2.3.6.7.12.12a-hexahvdro-2~n~1uu,uu~/'~,,t:ll,~1~-(1.2,3,4-tetrahvdro-6-naPhthvl))-Pvrazino~2',1':6,11pvridor3 4-blindole -1.4-dione The same two step procedure but startir~g from cyclopropylmethylamine and i"' , - " ' 17 gave, after re~r~r ' "' ' ~ from _;: Idl lu.~ dl ,e, the title comPound as white crystals m.p.: 125C.
Analysis for C2gH2gN302 (0 25 H2O):
C~lr~ C,75.73;H,6.70;N,9.46;
Found:C,75.45;H,6.86;N,9.14%.
Example 50 Cis-2.3.6.7.12.12a-hexahvdro-2-methvl-6-(2-naPhthvl) PVrazino~2'.1':6.1 lPvrido~3.4-blindole -1 .4-dione The same two step procedure but starting from methylamine and i,.t~,.",edidl~ 18 gave, after recry ' "' ' I from ~ ,lllolulllt:~lldll~ ll,d,lol, the title compound as white crystals In~p.: >260C.
Analysis for C2sH21 N3O2 (0 25H2o):
C~lrJ~' ' ' C,75.08;H,5.42;N,10.51;
Found:C,75.35;H,5.42;N,10.49%.
Exam~le 51 Cis-2.3.6.7.12.12a-hexahvdro-2-l~utvl-6-(2-thienvl)-Pvrazino~2~ 6~1lpvrido~3~4 blindole -1 .4-dione W0 95/19978 F~ 16J

The same two step procedure but starting from butylamine and illLe:lllle.lidl~ 20 gave, after recry~ldllisd~ from ethanol, the title comPound as white crystals m.p.: 226C.
Analysis for C22H23N3O2S:
C~lr~' ' C,67.15;H,5.89;N,10.68;
Found:C,67.39;H,5.88;N,10.77%.
ExamDle 52 Cis-2.3.6.7.12.12a-hexahvdro-6-(5-bromo-2-thienvl)-2-methvl-pyrazino~2', 1':6.1 lPvridor3.4-blindole -1 ,4-dione The same two step procedure but starting from methylamine and il l ~ . lll~did~t: 24 gaYe, after, ~ " " , from ethanol, the title comPound as a cream powder m.p.: 258C.
Analysis for C1gH16BrN302S:
C~lr,~ tP~l C,53.03;H,3.75;N,9.76;
Found:C,~3.01 ;H,3.78;N,9.69%.
ExamPle 53 Cis-2.3.6,7, 12.1 2a-hexahvdro~-(4-bromo-2-thienvl)-2-methvl-Pvrazino~2'~1~:6.1 lPvrido~3~4-blindole -1 ,4-dione The same two step procedure but starting from methylamine and i"~..", " ' 26 gave, after recry " , from ethanol, the title compound as white crystals mp.: 292C.
Analysis for C1 gH1 6BrN302S (0 25H2o):
C~lrl~' ' ' C,52.48;H,3.82;N,9.66;
Found:C,52.46;H,3.81 ;N,9.60%.
ExamPie 54 Cis-2.3.6.7. 12.1 2a-hexahvdro-6-(5-bromo-2-thienvl)-2 cvcloPropvlmethvl-Pvrazinor2'~ 1':6.1 lPvrido~3.4-blindole-1 .4-dione The same two step procedure but starting from cyclopropylmethylamine and ill ..lllt:did~ 24 gaYe, after recr~, " , from ethanol, the title compound as white crystals m.p. :190C.
Analysis for C22H20BrN3O2S:
35 C~lcl~ l C,56.18;H,4.29;N,8.93;

W0 95/19978 ` `: . s ~ 183 ~181377 Found:C,55.92;H,4.28;N,8.74%.
ExamPle 55 Cis-2.3.6.7.12.12a-hexahvdro-6-(5-bromo-2-thienvl)-2-cvcloPent Dvrazinor2'. 1':6,1 lPvridor3~4-blindole -1 .4-dione The same two step procedul e but starting from cyclopentylamine and edidL~ 24 gave, after recry ' " " ~ from ethanol, the title compound as white crystais m.p.: 252C.
Analysis for C23H2~ 3O2S:
CAICI' ' C,57.03;H,4.58;N,8.67;
Found:C,56.87;H,4 66;N,8.68%.
ExamPle 56 Cis-2.3,6,7,12,12a-hexahvdro-2-rnethvl-6-(5-methvl-2-thienvl)-Pvrazinor2~ 6~1 lpvridor3~4-blindole -1 ~4-dione The same two step procedure but starting ~rom methylamine and the cis isomer of i~ didL~ 66 gave, after recr~ from ethanol, the title compound as white crystals m.p.: 282C.
Analysis for C20H1 gN3o2s ( 2'jH2):
CAIrlIIA1C~rI C,64.93;H,5.31;N,11.36;
Found:C,64.84;H,5.28;N,10.81%.
ExamPle 57 Cis-2.3.6.7.12.12a-hexahvdro-2-rnethvl-6-(3-thienvl)-Pvrazinor2l.1':6,1 lPvridor3~4-blindole -1 .4-dione The same two step proceclure but starting from methylamine and i"~.. ",e,iidL~: 22 gave, after recr~ from acetone, the title compound as white crystals m.p.: 290-295C.
Analysis for C1 gH1 7N3O2S:
CAI~IIIAt~-~ C,64.94;H,4.88;N,11.96;
Found: C, 64.81; H,4.95; N,11.68%.
ExamPle 58 Cis-2.3.6.7. 12.1 2a-hexahVdro-2-butvl~-(3-thienvl)-Pvrazinor2'. 1':6,1 lPvridor3~4 35 tlindole-1.-~dione W0 95/19978 2 1 8 1 3 7 7 P~ lo~ ~

The same two step procedure but starting from butylamine and i, ll~ didlcl 22 gave, after ,~-,"~ from methanol, the title comoound as white crystals m.p.: 236-239C.
Analysis for C22H23N3O2S:
CRlr~ l C,67.15;H,5.89;N,10.68;S,8.15;
Found:C,67.42;H,5.76;N,10.57;S,8.01%.
Example 59 Cis-2.3.6.7.12.12a-hexahYdro-2-methyl-6-(3-furyl)-pyrazinor2l~1l:6 1lpyridor3~4 blindole-1.4-dione The same two step procedure but starting from methylamine and the cis isomer of i"' ", " ' 28 gave, after recrY ' " " ~ from ether, the title compound as a white solid m.p.: 250C.
Analysis for C1 gH1 7N303 (0.5H20):
CAIr~ t~rl C,66.27;H,5.27;N,12.20;
Found:C,66.33;H,5.48;N,12.02%.
ExamDle 60 Cis-2.3.6.7. 12.1 2a-hexahYdro-2-methyl-6-(5-methyl-2-furvl) pyrazinor2',1':6,1lpyridor3,4-blindole-1,4-dione The same two step procedure but starting from methylamine and i"'~,""edidl~ 29 gave, after recr~ " , from ethanol, the title comPound as a cream powder m.p.: 303C.
Analysis for C20H1gN3o3 (0 25H2o):
CRIrl IIRtl-rl C,67.88;H,5.55;N,1 1.87;
Found:C,67.90;H,5.50;N,1 1 .98%.
ExamPle 61 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-methYI-6-(4-" ,.,;~ ,I ,e, I~l)-pyrazinor2'.1':6,11PYridor34-blindole-1.4-dione The same two step procedure but starting from methylamine and i"l~""edid~ 31 gave, after recry: " , from ethanol, the title compound as white crystals m.p. :>260C.
Analysis for C22H21 N3O2 (0 25 H2O):
CRlr~ IIRt~ C,72.61 ;H,5.~5;N,1 1 .55;

21813~7 W0 9S/19978 ` r.~ 7~ 0J

Found:C,72.73;H,5.96;N,1 1.59%.
Exam~le 62 Cis-2.3.6.7. 12,1 2a-hexahvdro-2-isoProPvl-6-(4-methvlPhenvl) Pvrazino~2'. 1':6.1 lPvridor3.4-blindole -1 ,4-dione The same two step procedure but starting from isopropylamine and i, I~el " - ' 31 gave, after recry ' " , fr~m the title comPound as v,/hite crystals m.p.:

Analysis for C24H2sN3o2 (0-5H20):
C~ C,72.70;H,6.61;N,10.60;
Found:C,73.06;H,6.43;N,9.66%.
ExamPle 63 Cis-2.3.6.7. 12,1 2a-hexahvdro-2-butvl-6-(4-methvlPhenvl)-Pvrazinor2~ 1':6.1 lPvrido~3.4-blindole -1 ,4-dione The same two step procedure but starting from butylamine and illLelllleui_'~ 31 gave, after recr~ " " , from methanol, the title compound as white crystals m.p.: 194C.
Analysis for C2sH27N3o2 (0 5H20):
C~ C,73.15;H,6.87;N,10.24;
Found:C,73.01 ;H,6.84.N,10.26%.
Example 64 Cis-2,3,6,7.12,12a-hexahvdro-2-cvcloproPvlmethvl-6-(4-methvlPhenvl)-Pvrazinor2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure l~ut starting from cyclopropylmethylamine and ill' Illeuid~e 31 gave, after recry ' " , from l~ ., the title comPound as white crystals m.p.: 1 94C.
Analysis for C2sH2sN3o2 (1 1 H2O) - C~lr~ . C,71.61;H,6.54;N,10.02;
Found:C,71 .42.H,6.07;N,9.95%.
ExamPle 65 W095119978 218i377 r~ 7i.'~ 183 Cis-2.3.6.7.12.12a-hexahvdro-2-methvl-6-r3-methvlPhenvl) Dvrazinor2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from ",~ I..."i"e and i"Lt:""adidL 33 gave, after recr~ ' " ' , from ethanol, the title comPound as white crystals m.p.: >260C.
Analysis for CzH21 N3O2:
CAIrll' ' ' C,73.52;H,5.89;N,11.69;
Found:C,73.60;H,5.97;N, 11 .66%.
ExamPle 66 Cis-2.3.6.7.12.12a-hexahvdro-2-butvl-6-(4-trifluoromethvlPhenvl) Pvrazinor2'. 1':6.1 lPvridor3~4-blindole -1 ,4-dione The same two step procedure but starting from butylamine and i"L~""e~i~,Lt, 35 gave, after recr~ from Ille~ d~o.J~ ', the title comPound as white 1 5 crystals m.p.: 1 55C.
Analysis for C2sH24F3N3o2 (0 5H20):
CAIr~ IIAtF-rl C,64.65;H,5.43;N,9.05;
Found:C,64.78;H,5.40;N,9.01 %.
ExamPle 67 Cis-2.3.6.7.12.12a-hexahvdro-2-methvl-6-(4-trifluu,u,,,~l;,ù~vPhenvl) Pvrazinor2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from methylamine and the cis isomer of i" Ill~-iidl~ 65 gave, after recr~ from methanol, the title comPound as white crystals m.p.: 174-180C.
Analysis for C22H18F3N3o3 (0 5H20):
CAIr~ IIAt~l C,60.27;H,4.37;N,9.58;
Found:C,60.24;H,4.28;N,9.50%.
ExamPle 68 Cis-2.3.6.7.12.12a-hexahvdro-2-methvl-6-(4-hvdroxvPhenvl) Pvrazinor2'. 1':6.1 lPYridor3~4-blindole -1 .4-dione The same two step procedure but starting from methylamine and didL~ 39 gave, after recr~ from methanol, the title comPound 35 as yellow crystals m.p. :179-1 80C.

~81377 WOgS/19978 :~ . . r~

Analysis for C21 H1 gN303(1 .25H20):
CA~ t~ C,65.70;H,5.64;N,10.94;
Found:C,65.46;H,5.45;N,10.92%
5 ExamPle 69 Cis-2.3.6.7.12.12a-hexahYdro-6-~3-hvdroxv-4-",~;:,u,~ I)e"~1)-2-methvl-PVrazino~2',1':6.1 lPvridor3.4-blinclole -1 .4-dione The same two step procedure but starting from methylamine and llllt7did~e 40 gave, after recr~ from ethanol, the title compound as white crystals m.p. :320C.
Analysis for C22H21 N34(-25H2):
CAI^I ~ ,j C,66.74;H,5.47;N,10.61;
Found:C,66.72;H,5.46;N,10.53%.
Example 70 Cis-2.3.6.7.12.12a-hexahvdro-6-(4-hvdroxv-3-methoxvPhenvl)-2-meth ~vrazinor2'. 1':6.1 lPvrido~3.4-blinr~ole -1 .4-dione The same two step proceclure but starting from methylamine and illlt:llllt:didle41 gave, after recr~ iu,, from di~lllolu~ dll~ dllol, the title comPound as yellow crystals m.p. :264-265C.
Analysis for C22H21 N304:
AI.^,II~At_r~ C,67.51;H,5.41;N,10.74;
Found:C,67.05;H,5.41;N,10.62%.
ExamDle 71 Cis-2.3.6.7.12.12a-hexahvdro-2-butvl-6-(4-cvd"r,~ "~l)-PVrazino~2'. 1':6,1 lPvrido~3.4-blindole -1 .4-dione The same two step procedure b~lt starting from butylar, ine and il l~ did~e: 37 gave, after recr~: " ", from methanollwater, the title compound as white crystals m.p.: 246C.
Analysis for C2sH24N42 (1 H2O) CAI^~ At-~I C,69.75;H,6.09;N,13.01;
Found:C,69.50;H,5.96;N,12.86%.
. 35 ExamPle 72 -W0 9S/19978 ~ ~ 8.1 3 7 ~ r~

cis-2~3~6~7~12~12a-hexahvdro-6-(4-ethvlphenvl)-2-isopr Pvrazino~2'.1':6.1lPvrido~3.4-blindole -1 .4-dione The same t\,vo step procedure but starting from isopropylamine and the cis isomer of i~ did~ 42 gave, after recry, " ", from n-pentane, the title comPound as v~hite crystals m.p.: 1 30C.
Analysis for C2sH27N3O2 (0.5H20):
C~lc~ ~' ' ' C,73. 15; H,6.87; N, 10.24;
Found:C,73.39;H,7.08;N,9.81%.
ExamDle 73 Cis-2.3.6.7. 12.1 2a-hexahvdro-6-(4~thvlPhenvl)-2~vcloPropvlmeth PVrazino~2'. 1':6.1 lPvrido~3.4-blindole -1 ,4-dione The same t~,vo step procedure but starting from cyclopropylmethylamine and the cis isomer of il,le""~id~ 42 gave, after recr~ " , from ethanol, the title comPound as v,lhite crystals m.p.: 160C.
Analysis for C26H27N32 C~lr~ t~ C,75.52;H,6.58;N,10.16;
Found: C ,75. 54; H ,6.62; N ,10.08% .
ExamPle 74 Cis-2.3.6.7. 12.1 2a-hexahvdro-6-(4-isoProPvlPhenvl)-2-meth Pvrazino~2', 1':6.1 lPvrido~3.4-blindole -1 .4-dione The same t~,vo step procedure but starting from methylamine and i" ",- ' ' 43 gave, after recry~ from ethanol, the title comPound as v,/hite crystals m.p.: 244C.
Analysis for C24H25N32 C~ ' ' C,74.39;H,6.50;N,10.84;
Found:C,74.27;H,6.53;N,1 1 .05%.
ExamPle 75 Cis-2.3.6.7.12.12a-hexahvdro-2-butvl-6-(4-nitroPhenvl) PVrazinO~2'.1':6.1 lPvrido~3.4-blindole -1 ~4-dione The same t\,vo step pror,edure but starting from butylamine and i, l~ didL~ 45 gave, after recrya~ ti.,,~ from methanol, the title comPound as white crystals 35 m.p.: 182C.

~ W0 95119978 ~ ¦ 8 13 ~ ~ r~"~l 7~ [i~
Analysis for C24H24N404 (0.25l~2o):
C~lr~lAt~ C,65.97;H,5.65;N,12.82;
Found:C,65.92;H,5.62;N,12.96%.
ExamPle 76 Cis-2.3.6.7.12.12a-hexahvdro-6-~Wimethvldl"i"uul~tj"~ 2-methvl-Pvrazinoi2~ :6~1lpvrido~3~4-blindole-1.4-dione The same two step procedure blJt starting from methylamine and the cis isomer of il l ~ didl~ 47 gave after recry " " , from methanol, the title compound as white crystals m.p.: 266C.
Analysis for C23H24N42 C~ 1 C,71.11;H,6.23;N,1442;
Found:C, 71.19; H, 6.24; N, 14.34%.
Example 77 Cis-2.3.6.7.12.12a-hexahvdro-2-l~ethvl-6-(3-Pvridvl) Pvrazinor2~ :6~1lpvridoi3~4-blindole-1.4-dione The same two step proce~ure but starting from methylamine and didl~:48 gave after recry ' " " ~ from ul~lulurullll, the title comPound as white crystals m.p.: 312C.
Analysis for C2oH1 8N42:
C~'^~ C,69.35; H,5.24;N, 16.17;
Found:C,69.08;H,5.20;N,16.19%.
ExamPle 78 (6R.12aR~-2,3.6.7.12.12a-Hexahvdro-2-methYi-6-(3~4-methvl~ diu~vphenvl) Pvrazinoi2'.1':6.11Pvridoi3.4-blindole -1 ,4-dione a) To a stirred solution of i, lle~l, ~ " 54 (0.5 9) and NaHCO3 (0.14 9) in anhydrous CHCI3 (20 mL) was added dropwise ..l llul uat~lyl chloride (0.27 mL) at ûC. The resulting mixtl ~re was stinred for 1 hour at the same le:lll~t:l ' Ire and diluted with (~HC13 (20 mL). Water (10 mL) was then added dropwise with stirring to the mixture, followed by a saturated solution of NaHC03. The organic layer was washed with water until neutrality and dried over Na2SO4. After evaporatit~n of the solvent under reduced pressure, 35 (6R.12aR)-methvl 1,2,3,4-tetrahvdro-2-,,~,lu,u~ivl-1-(3,4-WO 95/19978 ~ 7 . `~ o~ ~

methylell~dioAvphenvi)-9H-Dvridor3,4-blindole-3-carboxvlate was obtained as an oil which was crystallised from ether to give a solid (0.38 9, m.p.: 233C) which was used without further purification in the next step.
b) To a stirred suspension of the ~ uact:lyl i"' ",edi.,~ (0.37 9) in MeOH
(20 mL) was added at room temperature a solution of methylamine (33% in EtOH) (0.4 mL) and the resulting mixture was heated at 50C under N2 for 16 hours. The solvent was removed under reduced pressure and the residue was dissolved in CH2CI2 (50 mL). After washing with water (3x20 mL), drying over Na2SO4 and evaporating to dryness, the residue was purified by flash ulllullldluu~ld~ eluting with CH2C12/MeOH (99/1) and recrystallised from 2-propanol to give the title compound as white crystals (0.22 9) m.p.: 302-303C.
Analysis for C22H1gN3O4:
CPIrlll ' ' C,67.86;H,4.92;N,10.79;
Found:C,67.77;H,4.92;N,1 0.74%.

[a]D = +71.0 (C=1.00; CHCI3).
The following compounds were obtained in a similar manner:
ExamDle 79 (6R. 1 2aR)-2.3.6.7. 12.1 2a-Hexahvdro-2-isoproPvl-6-(3,4-methvl~, ,e.liuAvPhenvl)-pvrazinor2~ 1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from i~uju~u,ujl~mine and il".:""edidL~:
54 gave, after recry~ from methanol, the title comPound as white crystals m.p.: 290-293C.
Analysis for C24H23N3O4:
C~lr~ t~ C,69.05;H,5.55;N,10.07;
Found:C,69.06;H,5.49;N,10.12%.

[a]D =+52.6 (C=1.14;CHC13).
35 ExamPle 80 W095/19978 ~,18~ 3`~ r~ C~-l83 (6R,12aR)-2,3,6,7,12,12a-Hexahvdro-2-butYl-6-r3.4-methvlenedioxvPhenvl) Pvrazino~2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure t~ut starting from butylamine and i"~ .", " ' 54 gave, after recrys " " ~ frolm tolue,~/l,tAd"e, the title compound as white crystals m.p.: 209-210C.
Analysis for C25H25N34 CAIr,~' '. C,69.59;H,5.84;N,9.74;
Found:C,69.70;H,5.93;N,9.74%.

[a]D = +50.2 (C=0.53; CHCI3) ExamPle 81 (6R, 1 2aR)-2,3.6.7. 12.1 2a-Hexahvdro-2-isobutvl~-(3.4-methvlel-~diu~Phenvl)-Pvrazino~2'. 1':6,1 lPvrido~3~4-blindole -1 .4-dione ~5 The same two step procedure t~ut starting from isobutylamine and i"~"" " ' 54 gave, after recry~ " , from methanol, the title compound as white crystals m.p.: 227-228C.
Analysis for C2sH2sN3O4:
C~lr,~ ~lAt~l C,69.59;H,5.84;N,9.74;
Found:C,69.52;H,5.87;N,9.74%.

[a]D = +45 (C=1.04; CHC13).
ExamPle 82 (6R. 1 2aR)-2.3.6.7. 12.1 2a-Hexahvdro-2-cvclopentvl-6-(3.4-methvlel~diu,~vphenvl)-pvrazinor2'.1':6.11Pvrido~3,4-blindole -1 ,4-dione The same two step procedure but starting from cy.,lu~ yl_."i"~ and ill~e~ 54 gave, after recry~ from ether, the title comPound as white crystals m.p.: 237-239C.
30 Analysis for C26H2sN3O4:
C~lr~' ' ' C,70.41;H,5.68;N,9.47;
Found:C,70.13.H,5.67.N,9.42%.

35 [a]D = +36.6 (C=0.98; CHCI3).

W0 9!i/19978 2 1 g ~ 3 7 7 ~ ' . lo~ --ExamPle 83 (6R.12aR~-2.3.6,7,12,12a H~,~dl,~,u-6-(3.4-methvlellediL,~vPhenvl)-2-cv~,lul ~ 1-Pvrazino~2'. 1':6.1 lPvrido~3.4-blindole -1 .4-dione The same two step procedure but starting from cyLlulle~y~ille~llylamine and the cis isomer of i" Ille~idte: 56 gave, afler recry " , from 2-propanol the title comPound as white crystals m.p.: 209C.
Analysis for C2gH2gN3O4:
C~lr~' ' C,71.32;H,6.20;N,8.91;
Found:C,71.30;H,6.29;N,8.74%.

[a]D = +40 0 (C=û.99; CHC13).
ExamDle 84 (6R, 1 2aR)-2.3.6.7. 12.1 2a-Hexahvdro-2-cvcloProPvlmethvl-6-(4-l, le~l lu,~,JI ,tsl l~l)-Dvrazino~2'. 1':6.1 lPvrido~3.4-blindole -1 .4-dione The same two step procedure but starting from cyclopropylmethylamine and ill Ille.lid~e 57 gaYe, afler recrys " ~ from methanol, the title comPound as white crystals m.p.: 2û4-205C.
Analysis for C2sH2sN3o3(o.5H2o):
C~ ' ' C,70.74; H,6. 17; N,9.90;
Found:C,70.98;H,6.09;N,9.92%.

[a]D = +54 1 (C=1.03; CHCI3).
ExamPle 85 (6R.12aR)-2.3.6.7.12.12a-Hexahvdro-2-butvl-6-(4-",~LI,u,~ "~
Pvrazinor2'.1':6.1lPvrido~3.4-blindole -1 .Wione The same two step procedure but starting from buylamine and illtelllle~idlt: 57 gave, after , eLI y~ " , from 2-propanol, the title compound as white crystalsm.p.: 183-184C.
Analysis for C2sH27N3o3(o 5H2o):
C~ tP~l C,70.40;H,6.62;N,9.85;
Found:C,70.55;H,6.64;N,9.92%.

O WO95/19978 2~3rt f r~ lo~

[a]D = +45 4 (C=1.04; CHCI3).
ExamPle 86 (6R,12aR~-2.3,67,12,12a-Hexahvdro-2-c~n,lu,,e,l~./l 6-(4-methoxvphenyl)-Pvrazino~2~ 6,1lPvrido~3.4-blindole-1.4-dione The same two step procedure but starting from c~ulu~ ,,t~l...,,i,,e and ill' IlleCIidL~ 57 gave, after recry ' "' " ~ from ether, the title compound as v,~hite crystals m.p.: 210-211C.
Analysis ~or C26H27N3O3 CA~r~ C,72.71;H,6.34;N,9.7'8;
Found:C,72.53;H,6.39;N,9.53%.

[a]D = +29.8 (C=1.07; CHCI3).
ExamDle 87 (6R. 1 2aR)-2. 3.6.7.12.1 2a-Hexahvdro4-(3-chloro-4-methoxvDhenvl)-2-cvclopropvlmethvl-pvrazino~2',1':6,11pvrido~3,4-blindole -1 .4-dione The same t~vo step procedure but starting from cyc~opropylmethylamine and illlt:lllle~idl 59 gave, after ,t:~y ' "' '' ~ from methanol, the title comooundas v"hite crystals m.p.: 218-21 9C.
Analysis for C2sH24ClN3O3 ~0 25 H2O):
CAlr~ J C,66.08;H,5.43;N,9.25; Cl, 7.80;
Found: C, 66.11; H, 5.33; N, 9.û3; Cl, 7.74%.

[alD = +49 4 (C=1.03; CHCI3).
Examr~le 88 (6R.12aR)-2,3.6,7,12,12a-Hexahvdro-2-cvclopentvl4-(3-ch~oro-4-",~tl,u~v,~ "~l)-Pvrazinor2',1':6,1lpvrido~3.4-blindole-1.4-dione The same two step procedul e but starting from cyclopentylamine and ill' Illedid~t: 59 gave, after recr~/ ' "' " ~ from methanoi, the title compoundas white crystals m.p.: 260-262C.
Analysis for C26H26CIN3O3:
35 C~ ' ' ' C,67.31 ;H,5.65;C1,7.64;N,9.06;
-WO 95/19978 ~ 7 ~ ~ . ID~ --Found:C,66.98;H,5.67;CI,8.06;N,9.04%.

[a]D = +27.6 (C=1.05; CHCI3).

ExamPle 89 (6R.12aR)-2.3.6.7,12.12a-Hexahvdro-6-(3-chloro-4-methoxYPhenvl)-2-methvl-PYrazino~2'. 1':6.1 lPvrido~3~4-blindole -1 .4-dione The same two step procedure but starting from methylamine and i~ edidL_ 59 gave, after recr~ from methanol, the title comPound as white crystals m.p.: 283-284C.
Analysis for C22H20CIN3O3:
C~ir~ l C,64.47;H,4.92;CI,8.65;N,10.25;
Found:C,64.49;H,4.92.CI8.33.N,10.02%.

[alD = +61.3 (C=1.00; CHCI3).
Example 90 (6R, 1 2aR)-2.3.6.7. 12.1 2a-Hexahvdro-2-isoProPvl-6-(3-chloro-4-methoxvPhenvl) Pvrazinor2'.1':6.11Pvrido~3,4-blindole-1,4-dione The same two step procedure but starting from isopropylamine and i"'u.", 59 gave, after recry ' " " ) from methanol, the title comPound as ~vhite crystals m.p.: 302-304C.
Analysis for C24H24CIN3O3:
C~lr~ t~l C,65.83;H,5.52;N,9.60;
Found:C,65.83;H,5.57.N,9.73%.

[a]D = +39 8 (C=0.95; CHC13).
Example 91 (6R, 1 2aR)-2.3.6.7. 12.1 2a-Hexahvdro-6-(2.3-dih~dl ubt~ u~blfuran-5-vl)-2-methvl-Pvrazino~2'.1':6.1 lPvrido~3~4-blindole -1 .4-dione The same two step procedure but starting from methylamine and i"~..", ' ' 61 gave, after recryO~dllisd~iù~ from diulllululll~ti~dl~ illdllol, the title comPound as white crystals m.p.: 288-291 C.

WO 95/19978 ~ 1 ~ 1 3 7 ~ r ~ c - lO~

Analysis for C23H21 N303:
C~ ' ' ' C,71.30;H,5.46;N,1C~.85;
Found:C,71 .27;H,5.49;N,10.96%.

[a]D = +65 6 (C=0.4; CHC13).
ExamPle 92 (6R.12aR)-2.3.6,7.12.12a-Hexa~lvdro-6-(2.3-dih~d~u~e,,~u~blfuran-5-vl~-2-1 û methvlcvclopropvl-pvrazino~2', 1 ' :6.1 lPvrido~3.4-blindole -1 .4-dione The same two step procedure but starting from methylcyclopropylamine and . " ' 61 gave, after recr~,~ldl,;~liùl~ from methanol, the title comPound as white crystals m.p.: 242-244"C.
Analysis for C26H25N33 CPlrlll~t~l C,73.05;H,5.89;N,9.~3;
Found:C,72.90;H,5.93;N,9.98%.

[a]D = +55 4 (C=0.99; CHC13).
ExamPle 93 (6R.12aR~-2,3,6,7,12.12a-Hexa~lvdro-6-(5-indanvl)-2-methvl-Pvrazino~2'. 1':6.1 lPvridor3.4-blindole -1 .4-dione The same two step procedure but starting from methylamine and i"~""e~idl~ 63 gave, after recr~ from methanol, the title compound 25 as white crystals m.p.: 262C.
Analysis for C24H23N32 C~l~ll' ' ' C,74.78;H,6.01;N,10.90;
Found:C,74.65;H,5.90;N,10.67%.

30 [a]D = +68.6 (C=0.98; CHCI3).
ExamPle 94 (6R,12aR)-2.3.6.7.12.12a-Hexallvdro-6-(5-indanvl)-2-CvCloPro~vlmeth PVrazinO~2'. 1':6.1 lPvrido~3,4-blindole -1 ,4-dione ",: ~
WO 9~i/19978 r~
2181~

The same two step procedure but starting from cyclopropylmethylamine and illLt~ didlt: 63 gave, after recr~ ' " ' , from methanol, the title comPound as white crystals m.p.: 176C.
Analysis for C27H27N3O2 (0.25H2o):
C~lr~ tF~d C,75.41; H, 6.45; N, 9.77;
Found:C, 75.25; H, 6.51; N, 9.75%.

[a]D = +~79 (C=1.00; CHC13).
ExamPle 95 (6R. 1 2aR)-2.3.6.7. 12.1 2a-Hexahvdro-2-methvl-6-(3.4-methvlenediu,~Phenvl)-r~vrazino~2'.1':6.1 lPvrido~3.4-blindole-1 .4-dione To a stirred suspension of Illte:lllleUidlt: 73 (12.59) in MeOH (400ml) was added at room temperature a solution of methylamine (33% in EtOH) (13.7ml) and the resulting mixture was heated at 5ûC under N2 for 14 hours. The soivent was removed under reduced pressure and the residue was dissolved in CH2CI2 (11).
Affer washing with water (3 x 500ml), drying over Na2SO4 and evaporating to dryness, the white solid obtained was recrystallised from 2-propanol to give thetitle comPound as white needles (7.59).
mp: 298-300C.

[a]D = + 71 3 (c = 0.55, CHC13).
Elemental analysis (C22H1gN3O4) ~ ll' ' C, 67.86; H, 4.92; N, 10.79;
found: C, 67.79; H, 4.95; N, 10.61%.
ExamDle 96 Cis-2.3.6.7. 12.1 2a-hexahvdro-2. 1 0-dimethvl-6-(3.4-methvl~,~ediù,~vPhenvl)-PvraZinO~2' . 1 ': 6. 1 1Pvrido~3.4-blindole-1 ,4-dione The same two step procedure as used to prepare Example 1, but starting from methylamine and the cis isomer of Ill~ llllediaic: 74, gave after recr~,aldlliadLiu,, from ethanol, the title comPound as white crystals m.p.: 275C.
Analysis for C23H21 N304 ( 0.4H20):
C~ : C, 67.27; H, 5.35; N, 10.23;
Found: C, 67.36; H, 5.21; N, 10.31%.
.

2~ ~137~
WO 95/19978 1 ~1I~J 7.,.'C 183 Example 97 (6R. 1 2aR)-2,3,6,7, 12.1 2a-Hexahydro-2-(3.4~i" ,~ UAvt~ I)-6-(3.4-methylelledioA~ I)-pvrazinor2~ 6,11Pvridor3.4-blindole-1.4-dione The same two step procedure as used to prepare Example 78, but starting trom veratrylamine and i"'~" - ' 54 gaYe, after recry~ " ~ from methanol, the title compound as white crysl:als m.p.: 224-226C.
Analysis for C3oH27N3o6:
CAIrlllAtF~d C,68.56; H,5.18; N,8.00;
Found: C,68.80; H,5.11; N,8.06%.

[a]D = + 43 9 (C = 1.02; CHCI3).
ExamPle 98 Cis-2.3.6.7.12,12a-hexahvdro-6-(4-~",i,1~ "~11)-2-butvl-Pvrazinor2'.1':6.1 lPvridor3.4-blinliole-1 .4-dione To a solution of Example 75 (1.5 9) in methanol (100 mL) was added SnCI2.H2O (3.06) and the resulting mixture was heated at reflux for 8 hours.
The mixlure was cooled to anbient lt~ p~ e, poured into ice and was adjusted to pH5 with 1N NaOH. The methanol was evaporated off and the residue was basified to pH11 with 1N NaOH and extracted with EtOAc (2 x 150 mL). After drying over Na2SO4 and evaporation of EtOAc, the resulting yellow powder was purified by radial ulllul ' _ ~ully eluting with CH2C12 to give the title comPound as a white powd~r (550 mg) m.p.: 1 92C.
Analysis for C24H26N4O2 (1 3 ~2):
CAIr~ C,67.68; H,6.77; N, 13.15;
Found: C,67.74; H, 6.68; N, 13.02%.
EAamDIe 99 Cis-2.3.6.7.12.12a-h~:Ac,l,~lu-6 (4-act~ id~ul,t~ 1)-2-butvl-Dvrazinor2'.1~:6,1 lDYridor3.4-blindole-1 ,4-dione To a solution of Example 98 (0.2. 9) in THF (15 mL) was added triethylamine (76 - ,uL) and acetyl chloride (39 ,uL) and the resulting solution was stirred at room temperature for 2 hours. After evaporation of THF, the resulting residue was . 35 taken up in CH2CI2 (100 mL), washed with water (2 x 50 mL) and dned over wo ss/lss78 2 1 8 1 3 7 7 P~ l c - lo ~ --Na2SO4. After evaporation of CH2CI2, the resulting solid was recrystallised from MeOH/H2O to give the title comPound as a cream powder (120 mg) m.p.:
246C.
Analysis for C26H28N43 CAIC~ C,70.25; H,6.35; N,12.60;
Found: C,69.85; H, 6.38; N,12.56%.
ExamDle 1 00 Cis-2.3.6.7. 12.1 2a-hexahvdro-2-butvl4-(4-methvl~ Idl I ~idu~17e~ Iyl)-Pvrazino~2~ :6~1 lpvrido~3~4-blindole-1 l4-dione To a solution of Example 98 (0.2 9) in THF (5 mL) was added triethylamine (228 ,uL) and ,,,c:~I,d,,6~ulfonyl chloride (126 ,uL) and the solution was heated at reflux for 6 hours. After evaporation of THF, the residue was taken up in CH2CI2, washed with water and dried over Na2S04. After u~/ap~,dlio~ of CH2C12, the residue was purified by radial ,l ll, d~l Iy eluting with CH2CI2/MeOH
(95/5) to give the title comDound as a brown powder (30 mg) m.p.: 1 88C.
Analysis for C2sH2gN404S (0.75 H2O):
CAlr.ll' ': C,60.77; H,6.02; N,11.34;
Found: C,60.61; H, 6.02; N,10.82%.
ExamPle 101 (6R, 1 2aR)-2.3.6.7. 12.1 2a-Hexahvdro4-(3.4-meth~l_ne-JioAvPhenvl)-Dvrazino~2', 1': 6.11 Pvrido ~3.4-bl indole-1.4-dione The same two step procedure but starting from ammonia and illlt:llll~didle: 54 gave, after recr~: ' " " , from methanol, the title comPound as white crystals m.p.: 285-290C.
Analysis for C21H,7N304:
C~lr'll~tPd: C, 67.19; H, 4.56; N, 11.19;
Found: C, 67.30; H, 4.66; N, 11.11 %.
[]20-D = + 88 (c = 0.48; pyridine).
Examr~le 1 02 (6R. 12aR)-2.3.6.7.12.12a-Hexahvdro4-(3.4-methvlel~ediuAYPhenvl)-2-(2-ProPvnvl)-Pvrazino ~2'. 1': 6.11 rJvrido ~3.4-bl indole-1,4-dione -W0 95119978 ~ i 8 1 3 ~ c l~

The same two step procedure but starting from ~updl~yl~ e and ill Ille~
54 gave, after recr~ from acetone, the title comPound as white crystals m.p.: 271 C.
Analysis for C24H1gN304:
CPlrll~ ': C, 69.72; H, 4.63; N, 1û.16;
Found: C, 69.95; H, 4.66; N, 10.06 %.
[ai20 D = + 51.7 (c = 0.49; CHC~3).
Example 103 (6R. 12aR)-2,3,6~7,12,12a-Hexa~lvdro-2-(3.4-methYlendioxvbenzvl)-6-(3.4-methvlenediuAvPhenvl)-pvrazinol!2l~ 1': 6.11 Pvrido r3.4-bl indole-1.4-dione The same two step procedure bLt starting from pit~u~yldlllilla and illLt:lll.- "54 gave, afler recry ' " " ~ from methanol, the title comPound as white crystals m.p.: 2û4-2û6C.
Analysis for C29H23N3O6:
C5~lr,ll~ d: C, 68.36; H, 4.55; N, 8.25;
Found: C, 68.25; H, 4.49; N, 8.41.
[a]20 D = + 43 (c = 1.û1; CHCI3~l.
ExamPle 1 û4 (6R. 12aR)-2,3.6.7.12.12a-Hexallvdro-2-(3,4~i,,,_~;,uAvPhenethvl)-6-(3.4-"n:~l"~ edi,oA~ "~I)-Pvrazino ~2'. 1': 6.11 Pvrido r3.4-bl indole-1.4-dione The same two step procedure l~ut starting from 3,4-dimethoxyphenethylamine and i"L~I",edidt~ 54 gave, after recry ' " ' ~ from ~i~.lllolulllt:tlld~ u~ r, the title comPound as white crystals m.p.: 265-266C.
Analysis for C31 H29N3O6:
C:llr~ lt~d: C, 69.ûO; H, 5,42; N, 7.79;
Found: C, 68.68; H, 5.35; N, 7.78 %.
[a]20 D = + 38.3 (c = 1.12; CHCI3).
Example 105 (6R, 1 2aR)-2.3.6.7. 12.1 2a-Hexahvdro-2-furfurvl-6-(3.4-methvl~i. ,e.liuA~Phenvl) PVrazino r2'. 1': 6.11 Pvrido r3.4 Ibl indole-1,4-dione W095/19978 ~81377; r~,1/r,l7.,.'[ 183 The same two step procedure but starting from furfurylamine and ill~elllled;~
54 gave, after recry " " ~ from methanol, the title comPound as white crystals m.p.: 219C.
Analysis for C26H21 N30s:
C~lr~ t~d: C, 68.56; H, 4.65; N, 9.23;
Found: C,68.16;H,4.63;N,9.15%.
[a]2D=+58.1(c=1.2;CHCI3) .

~xamole 106 (6R, 12aR~-2.3,6,7,12.12a-Hexahvdro-6-(3.4-methYle, le,JioxvPhenvl)-2-(2-thienvlmethvl)-pyrazino r2'. 1': 6.11 Pvrido ~3.4-bl indole-1,4-dione The same two step procedure but starting from 2-llliù~ ellelllelll~lamine and i" 1 l l " ' 54 gave, after recry,. " " I from " le~l Idl IUI/Y/-~'`', the titlecompound as white crystals m.p.: 155-1 57C.
Analysis for C26H2, N304S:
CAlr,~ t~d: C, 66.23; H, 4.49; N, 8.91; S, 6.8;
Found: C,66.13;H,4.54;N,9.12;S,6.78%.
[a]20 D = + 70.4 (c = 1.03; CHCI3).
ExamPle 107 (6R, 12aR~-2,3.6,7.12.12a-HexahYdro-6-(4-l"cillu,~ c~ 1)-2-methvl-pvrazino r2'. 1': 6.11 Pvrido r3.4-bl indole-1,4-dione The same two step procedure but starting from ",eil,~l..."i"e and illlellll~ " '57 gave, after recr~: " ", from methanol, the title comPound as white crystals m.p.: 285-288C.
Analysis for C22H2, N303:
C~r~ ' ': C, 70.38; H, 5.64; N, 11.19;
Found: C, 70.31; H, 5.69; N, 11.29 %.
~a]20 D = + 59 (c = 1.19; CHCI3).
ExamPle 1 08 (6R, 1 2aR)-2.3.6.7. 12.1 2a-Hexahvdro-2-ethYI-6-(4-methoxvPhenYl)-pyrazino r2' .
1: d,11 Dvrido 13.4-bl indol~-1 4-dione W095/19978 ?'L~3~

The same two step procedure bl~t starting from ethylamine and illL~Illledidk: 57gave, after recry ' "' '' :l from methanol, the title comPound as white crystalsm.p. : 277C.
Analysis for C23H23N3O3 CAlr,~ d: C, 70.93; H, 5,9!5; N, 10.79;
Found: C, 70.90; H, 5.96; N, 10.54 %.
[a]20-D = + 52 (c = 1.28; CHCI3).
ExamDle 109 (6R. 12aR)-2,3,6,7,12,12a-hexahvdro-6-(7-(4-methvl-3.4-dihvdro-2H-benzor1,4loxazinvl))-2-methvl-Pvrazinor2'.1': 6.11Pvridor3,4-bl indole-1,4-dioneThe same two step procedure but starting from i, I~ell ", " ' 75 and methylamine gave, after recry ' "' ", from ethanol, the title compound as white crystals m.p.: 285-288C.
Analysis for C24H24N4O3 (0.5 H2O):
CAlr~lAt~d: C, 67.75; H, 5.92; N, 13.17;
Found: C, 68.02; H, 6.00; N, 13.18 %.
[a]20-D = + 71.7 (c = 1, pyridine).
ExamPle 110 (6R. 1 2aR)-2.3.6.7. 12.1 2a-Hexa~Ydro-6-(5-(N-b~, ,~1';., "i. ,~/1))-2-methYI-pyrazinor2'. 1 ': 6. 1 lPYrido~3.4-blilldole-1 .4-dione The same two step procedure but starting from illtt:llllt:did~ 77 and methylamine gave, after recry_' "' " ~ from d;~.lll~lulll~ dllc,'",tltl,d"ol, the title compound as white crystals In~p~: 223-225C.
Analysis for C30H28N4O2:
CAlr,~' ' ': C, 75.61; H, 5.92; N, 11.76;
Found: C, 75.2; H, 5.78; N, 11.67 %.
[a]20-D = + 20.4 (c = 0.5, CHCI3).
ExamDle 11 1 (6R. 1 2aR)-2.3.6.7. 12.1 2a-Hexa~vdro-6-(5-indolinvl)-2-methyl-pyrazinor2', 1 ':
6,1 1pyridor3,4-blindole-1 ,4-dione A solution of Example 110 (1.05 9, 2.2 mmol) in methanol (100 mL) was h~dluyt:lld~l;d in the presence of 10 % Pd-C (100 mg) for 48 hours at room WO95/199?8 ~18~377 . . r~~ c-iO~ --temperature. After removal of the catalyst, the solvent was evaporated in vacuo to leave a residue which was purified by flash ~ lulll.lLuuld,ully eluting with di~lllUlUIII_; lallC/~ lldllUI 96/4. The solid obtained was recrystallised from cli,,l,lu,u,,,~;:,d,,e/methanol to give the title comPound (300 mg) as white crystals 5 m.p.:240C.
Analysis for c23H22N4O2 (0.5 H2O):
C~ ' ' ': C, 69.86; H, 5.86; N, 14.17;
Found: C, 70.13; H, 5.77; N, 14.06 %.
[]20-D = + 55.9 (c = 1.18; pyridine).

ExamPle 112 Cis-2.3.6.7,12,12a-heAdl,~dlu~6-(/1~ e~1)-2-methvl-Pvrazino~2l~1 6,1 lPvrido~3.4-blindole-1 .4-dione The same two step procedure but starting from methylamine and the cis isomer of il l~l ll 113did~ 42 gave, after recr~, " ' ., from methanol, the title comPound as white crystals m.p.: 254C.
Analysis for C23H23N3O2 (0 25 H2O):
CAI~ tPd C, 73.09; H, 6.27; N, 11.12;
Found: C, 73.03; H, 6.18; N, 11.36 %.
EAamPIe 113 (6R. 12aR)-2,3.6.7.12.12a-Hexahvdro-6-(4~d,uu,,,~l,uAvPhenvl)-2-meth PVrazino~2'. 1 ': 6. 1 1Pvrido~3.4-blindole-1 ,4-dione The same two step procedure but starting from ill~t:lllle:did~ 78 (cis isomer) and methylamine gave, after recr~: " ' l from methanol, the title compound as white crystals m.p.: 3û8-312C.
Analysis for C23H2,N3O4:
C~ : C, 68.47; H, 5.25; N, 10.42;
Found: C, 68.76; H, 5.18; N, 10.35 %.
[a]20 D = ~ 97.7 (c = 1, pyridine).
ExamPle 114 (5aR. 12R. 14aR)-1.2.3.5a.6.11.12.14a-Octahvdro-12-(3.4-methvlenediûAvPhenvl)-pvrrolo~ 2ll 4'.5'1Pvrazino~2'.1': 6,11pvrido~3,4 35 blindole-5-1.4-dione -WO95/19978 ~18t 377 ~ r~ 183 A solution of i~ didlt: 80 (0.7 9, 1.2 mmol) in a mixture of methanollTHF
(80/40 mL) was h~d,u~er, ' ' in the presence of 10 % Pd-C (75 mg) for 48 hours at 40C. After removal o~' the catalyst, the solvent was evaporated in Yacuo to leave a residue, which was purified by flash Glllu~ ,ully eluting with di~,lllu~ul~ ldllo~ ; ,d,~ol : 9812. The white solid obtained was recrystallised from methanol to give the title comr~ound (180 mg) as white crystals m.p.: 284-287C.
Analysis for C24H21N34 C~ Ad: C, 69.39; H, 5.10; N, 10.11;
Found: C,69.47;H,5.11;N,!~.97%.
[a]20 D = + 21.7 (c = 0.64, CHCI3).
ExamDle 11 5 (5aR, 12R, 14aS)-1,2,3,5,6,11,12,14a-Octahvdro-12-(3,4-methvl~,~ediu,~ llil)-DYrrolor1ll~2ll: 4',5'1Dvrazinor2',1': 6,1lDvridor3,4-blindole-5-1 .4-dione A solution of illl~lllledidlt: 81 (1~,8 9, 1.37 mmol) in methanol (40 mL) was hyd,ugel7dle:d in the presence o~ 10 % Pd-C (100 mg) for 5 h at 45C. After removol of the catalyst the solverlt was evaporated in vacuo to leave a residue,which was punfied by flash ulllullldlu~ld~ull~ eluting with ~i~lllolul,,~il,d,,c/,,,t:~,,d,,ol: 98/2. The solid obtained was recrystallised from methanol to give the title comp~und (300 mg) as white crystals m.p.: 302-304C.
Analysis for C24H21N34 C~ t~d: C, 69.39; H, 5.1~); N, 10.11;
Found: C,69.35;H,5.11 ;N, 10.10%.
[a]20 D = + 106.8 (c = 1.08, CHCI3).
- ExamDle 116 (3R, 6R, 12aR)-2,3,6,7,12,12a-hexahvdro-2,3-dimethvl-6-(3,4-meth~lel~e~iu,~vPhenvl)-Dvrazinor2l~ 1 ': 6, 1 lDvridor3,4-blindole-1 ,4-dione To a stirred solution of illl~ dial~ 82 (0.15 9, 0.34 mmol) in THF (15 mL) was added at room temperature a soll~tion of methylamine (33 % in EtOH) (0.32 mL) WO 95/19978 ~ 1 8 1 3 7 7 . ~ 7~.'C~

and the resulting solution was heated at reflux under N2 ~or 24 hours. The solvent was removed under reduced pressure and the residue was dissolved in CH2CI2 (25 mL). After washing with water (2 x 20 mL), drying over Na2SO4 and evaporatin3 to dryness, the cnude product was purified by flash .,I Ilu,,, ~UU~d,UI l~
S eluting with /di~ UIUIII~ dlle~ ld~lOl 99/1. The white solid obtained was recrystallised from methanol to give the title comPound as white crystals (80 mg) m.p.: 219-220C.
Analysis for C23H21N34 C~lr,~ C, 68.47; H, 5.25; N, 10.42;
Found: C, 68.39; H, 5.21; N, 10.42%.
[a]20 D = + 89.6 (c = 1; CHCI3).
Example 117 (3S. 6R, 1 2aRl-2,3.6,7, 12,1 2a-hexahydro-2,3-dimethvl-6-r3.4-methYlt:"~iuA~Dhenyl)-pyrazino~2' ,1 ': 6.1 lPYrido~3.4-blindole-1 .4-dione To a stirred solution of i, ~ didLL 83 (0.3 9, 0.68 mmol) in THF (30 mL) was added at room temperature a solution of methylamine (33 % in EtOH) (0.68 mL) and the resulting solution was treated at reflux under N2 for 6 days. The solvent was removed under reduced pressure and the residue was dissolved in CH2CI2 (50 mL). After washing with water (2,25 mL), drying over Na2SO4 and C~ UIdlil l9 to dryness, the crude product was purified by flash .,11l u~ u~ dyl ~y eluting with di~ lO~U~e:tild~ lle~l~d~OI 9911. The oily residue obtained was crystallised from methanol to give the title compound as white crystals (40 m~) m.p.: 307-309C.
Analysis for C23H2~ N304:
C~lr~ tPd: C, 68.47; H, 5.25; N, 10.42;
Found: C, 68.35; H, 5.33; N, 10.42%.
[a]20 D = + 65.2 (c = 1.15; CHCI3).
ExamDle 118 (6R. 12aR)-2.3.6.7.12.12a H~Adl,~dlu-6-(3.4-dil,~rd,uA~ d"~ 2-methvl-DYrazino~2'. 1': 6.11PYrido~3,4blindole-1,4-dione A solution of illle~llledidlt~ 86 (0.75 9; 1.34 mmol) in a mixture of ethanol/THF
(70/30 mL) was hydluul;lld~:d in the presence of 10 % Pd-C (75 mg) for 24 h at 35 room temperature. After removal of the catalyst, the solvent was evaporated in O WO95/19978 ~ 377 Y~l/~l7~tDIo.5 vacuo to leave a white solid which was recry ' " ' from methanol to give the title compound (0.35 9) as w~lite crysta~s m.p.: 224-226C.
Analysis for C21H,9N3O4:
Csllr~ ^i C, 66.83; H, 5.07; N, 11.13;
Found: C, 66.58; H, 5.01; N, 11.04 %.
[a]20oD = + 58.4 (c = 1.04; pyridine).
ExamPle 119 (6R.12aR)-2,3,6,7,12,12a-Hexahvdro-2-methvl-6-r5-(2-I"_;~ I))Dvrazino!2',1': 6.11Pvrido!3.4blindole-1,Wione The same two steps procedure but starting from i" ",edid~ 87 and methylamine gave a crude oil which was purifled by flash ~ U~dlUy~d,ully eluting with di~,l llUl Ul l le:~l ldl l~ i ldl lUI/tl ;_~ l lil le 92/8/0.1 %. The solid obtained was recrystallized from isu~lu,ud~ol~plu,uyl ~I,e,/v.~, to give the title compound (20 mg) as off-white crystals m.p.: 236C.
Analysis ~or C24H24N4O2 (2 68 ~2) C~r~ C, 64.23; H, 6.59; N, 12.48;
Found: C, 64.21; H, 6.43; N, 12.02 %.
[a]20 D = + 61.1 (c = 0.5; CH301~).
Exam~le 120 Compounds of formula (I) have been included in pharmacy formulations and details of such formulations are given below.

A. Direct Cu"",,~io"
1. mg/tabl~t Active ingredient 50.0 Crospovidone USNF 8.0 Magnesium Stearate Ph Eur 1.û
Anhydrous Lactose 141 .û

WOgS119978 2~8~377 r~

The active ingredient was sieved and blended with the excipients. The resultant mix was ~,,,,u, ~ased into tablets.
2. mg/tablet Active ingredient 50.0 Colloidal Silicon Dioxide 0,5 Crospovidone 8.0 Sodium Lauryl Sulphate 10 Magnesium Stearate Ph Eur 1.0 Microcrystalline Cellulose USNF 139.5 The active ingredient was sieved and blended with the excipients. The resultant mix was ~" ,~, ~a~d into tablets.
B. WET GRANULATION
1. mg/tablet Active ingredient 50.0 Polyvinyl pyrollidone 150.0 Polyethylene glycol 50.0 Polysorbate 80 10.0 Magnesium Stearate Ph Eur 2.5 C,u~c~,,,,~,ll.,ae Sodium 25.0 Colloidal Silicon Dioxide 2.5 Microcrystalline Cellulose USNF 210.00 The polyvinyl pyrollidone, polyethylene glycol and polysorbate 80 were dissolved in water. The resultant solution was used to granulate the active ingredient. After drying the granules were screened, th~n extruded at elevated temperatures and pressures. The extrudate was milled and/or screened then was blended with the microcrystalline cellulose, ,lUaCdllll_"OSe sodium, colloidal silicon dioxide and magnesium stearate. The resultant mix was c~;" ",u, ~_~sed into tablets.

2~ ~ 377 W09~5119978 r~ o~S

2. mg/tablet Active ingredient 50.0 ~lysol L ' 80 3.0 Lactose Ph Eur 178.0 Starch BP 45.0 P,t geld~i"iaad Maize Starch BP 22.5 Magnesium Stearate BP 1.5 The active ingredient was sieved and blended with the lactose, starch and ~.lt ut Idli"iaed maize starch. The polysorbate 80 was dissolved in purified water. Suitable volumes of the polysorbate 80 solution were added and the powders u~ere granulated. After drying, the granules were screened and blended wiLh the magnesium stearate. The granules were then ,u",,u,t,aaad into tablets.
Tablets of other strengths may be prepared by altering the ratio of active ingredient to the other excipients.
FILM COATED TABLETS
The drul t ",t "~io,~ed tablet formulations were film coated.
Coating S~ ) h wlw Opadry whitet 13.2 PurifiedwaterPh Eur to 100.0~
~ The water did not appear in the final product. The maximum ll ,eul ~:~iwl weight of solids applied during coating ~vas 20mg/tablet.
t Opadry white is a proprietary material obldi"dL le from Colorcon Limited, UK
which co~tains hydroxypropyl ",t~ lr,ell.llose, titanium dioxide and triacetin.
The tablets were film coated using the coaling susperlsion in conventional film coating equipment.

WO 9~ 9978 ' i ~- f ~ hl ~r.'~ l~s CAPSULES
1. rng/capsule Active ingredient 50.0 Lactose 148.5 Polyvinyl pyrollidone 100.0 Magnesium Stearate 15 The active ingredient was sieved and blended with the excipients. The mix was filled into size No. 1 hard 3elatin capsuies using suitable equipment.
2., I ,y,~ .
Active ingredient 50 0 Microcrystalline Cellulose 233.5 Sodium Lauryl Sulphate 3.0 Clu~ ;June 12.0 Magnesium Stearate 1.5 The active ingredient was sieved and blended with the excipients. The mix was filled into size No. 1 hard gelatin capsules using suitable equipment.
Other doses may be prepared by alterin3 the ratio of active ingredient to excipient, the fill weight and if necessary changing the capsule size.
3. ...~.'c lj 1' Active ingredient 50 0 Labrafil M1944CS to 1.0 ml The active ingredient was sieved and blended with the Labrafil. The suspension was filled into soft gelatin capsules using dUUI Uprid~t: equipment.
ExamDle 121 Inhibitorv effect on cGMP-PDE
cGMP-PDE activity of compounds of the present invention was measured using a one-step assay adapted from Wells at al. (Wells, J. N., Baird, C. E., Wu, Y. J.

~ W0 95/19g78 `~ ~8 ~37 ~

and Hardman, J. G., Biochim. Biophys. Acta 384, 430 (1975)). The reaction medium contained 50mM Tris-l~Cl,pH 7.5, 5mM Mg-acetate, 250~1gtml 5'-uli~ e, 1mM EGTA and 0.1511M 8IH3]-cGMP. The enzyme used was a human, ~,u,, ILil Idl ,l PDE V (ICOS, Seattle USA).

Compounds of the invention werl3 dissolved in DMSO finally present at 2% in the assay. The incubation time was 3û minutes during which the total substrate conversion did not exceed 30%.
The ICso values for the compounds examined were dt~ ""i"ed from cu, ,c~"~, dliùl ,-response curves l~sing typically ~ul ,c~, Itl dliul ,~ ranging from 10nM to 10~1M. Tests against other PDE enzymes using standard ,n~:~l,ûd~lu~y also showed that compounds of t~le invention are highly selective for the cGMP
specific PDE enzyme.
-cGMP level measurements Rat aortic smooth muscle cells (R~MC) prepared according to Chamley et al. in Cell Tissue Res. 177, 503 - 522 (1977) were used between the 10th and 25th passage at confluence in 24-well culture dishes. Culture media was aspirated 20 and replaced with PBS (0.5ml,l cu"~.. ;. lil ,9 the compound tested at the d~ltJIU,UI idtel co"c~"t,dliOI~. After 30 minut2s at 37C, particulates guanylate cyclase was stimulated by additiol1 of ANF (100nM) for 10 minutes. At the end of incubation, the medium was withdrawn and two ~tldU~iUi~ were performed by addition of 65% ethanol (0.25ml). The two ethanolic extracts were pooled and evaporated until dryness, using a Speed-vac system. c-GMP was measured after acetylation by ~ lilld~iUI ~ proximity immunoassay (AMERSHAM).
The compounds according to the present invention were typically found to exhibit an ICso value of less than 500nM, and an ECso value of less than 5. In vitro test data for I t~ 51 1td~ compounds of the invention is given in following Table 1:

WO 95/19978 ~ Sl 3 7 7 1 ~, I/hl ,s. ~ 183 Table 1 Example No. IC50 nM EC60 IlM
12 10 0.15 36 <1 0 0.5 52 20 0.8 63 30 0.35 79 <10 0.15 82 20 0.5 84 10 0.4 89 10 <0.1 2 0.2 101 10 0.3 115 <10 0.4 ExamDle 122 -Antihv~ertensive activitv in rats The hypotensive effects of compounds according to the invention as identified intable 2 were studied in conscious a~ dl ~eously hypertensive rats (SHR). The compounds were a~l";"ial~,~d orally at a dose of 5mg/kg in a mixture of 5/0 DMF and 95% olive oil. Blood pressure was measured from a catheter inserted in the carotid artery and recorded for 5 hours after ddlllillialldliol1. The results are eA,lJI ~ased as Area Under the Curve (AUC from 0 to 5 hours, mmHg.hour) of the fall in blood pressure over time.
In Vivo Results Example No. AUC PO (mmHg.h) ~181377 r~ll~7r~
Example No. 13~

Claims

1. A compound of formula (I) and salts and solvates thereof, in which:
R o represents hydrogen, halogen or C1-6 alkyl;
R1 represents hydrogen, C1-6alkyl, C2-4 alkenyl, C2-5 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkyC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl;
R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3-or 4- membered alkyl or alkenyl chain.

2. A compound of formula (1a) and salts and solvates thereof, in which:
R o represents hydrogen, halogen or C1-6 alkyl;
R1 represents hydrogen, C1-6alkyl, haloC1-6alky, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl; and R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen.

3. A compound according to Claim 1 or 2, wherein R° represents hydrogen

4. A compound according to any of Claims 1 to 3, wherein R1 represents hydrogen, C1-4alkyl, haloC1-4alkyl, C3-6cycloalkyl, C3-6cycloalkylmethyl, pyridylC1-3alkyl, furylC1-3alkyl or optionally substituted benzyl.

5. A compound according to any of Claims 1 to 3, wherein R1 and R3 together represent a 3-membered alkyl chain.

6. A compound according to any of Claims 1 to 4, wherein R3 represents hydrogen.

7. A compound according to any of Claims 1 to 6, wherein R2 represents an optionally substituted benzene, thiophene, furan, pyridine or naphthalene ring or an optionally substituted bicyclic ring where n is 1 or 2 and X and Y are each CH2 or O.

8. A cis isomer of formula (I) represented by formula (Ib) and mixtures thereof with its cis optical enantiomer, including racemic mixtures, and salts and solvates of these compounds in which R o is hydrogen or halogen and R1, R2 and R3 are as defined in any one of claims 1 to 7.

9. A compound selected from:
Cis-2,3,6,7,12,12a-hexahydro-2-(4-pyridylmethyl)-6-(3,4-methylenedioxy-phenyl)-pyrazino[2', 1' : 6,1]pyrido[3,4-b]indole-1,4-dione;
Cis-2,3,6,7,12,12a-hexahydro-6-(2,3-dihydrobenzo[b]furan-5-yl)-2methyl-pyrazino[2',1':6,1]-pyrido[3,4-b]indole -1,4-dione;
Cis-2,3,6,7,12,12a-hexahydro-6-(5-bromo-2-thienyl)-2-methyl-pyrazino-[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;
Cis-2,3,6,7,12,12a-hexahydro-2-butyl-6-(4-methylphenyl)-pyrazino-[2',1':6,1 ]pyrido[3,4-b]-indole-1,4-dione;
(6R,12aR)-2, 3,6,7,12,12a-Hexahydro-2-isopropyl-6-(3,4-methylenedioxy-phenyl)-pyrazino-[2',1':6,1 ]pyrido[3,4-b]indole -1,4-dione;
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopentyl-6-(3,4-methylene-dioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-cyclopropylmethyl-6-(4-methoxyphenyl)-pyrazino-[2',1':6,1]pyrido[3,4-b]indole -1,4-dione;
(6R,12aR)-2, 3,6,7,12,12a-Hexahydro-6-(3-chloro-4-methoxyphenyl)-2-methyl-pyrazino-[2',1':6,1]pyrido[3;4-b]indole -1,4-dione;
(6R,12aR) 2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino-[2',1':6,1 ]pyrido[3,4-b]indole-1,4-dione;
(6R, 12aR)-2,3,6,7,12,12a-Hexahydro-6-(3,4-methylenedioxyphenyl)pyrazino[2', 1' ;6,1 ]-pyrido [3,4-b] indole-1,4-dione;
(5aR, 12R, 14aS)-1,2,3,5,6,11,12,14a-Octahydro-12-(3,4-methylenedioxy-phenyl)-pyrrolo[1",2" : 4',5']pyrazino[2',1' : 6,1]pyrido[3,4-b]indole-5-1,4-dione;
and physiologically acceptable salts and solvates thereof.

10. (6R,12aR)-2, 3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxy-phenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole -1,4-dione; and physiologically acceptable salts and solvates thereof.

11. A compound of formula (I) as defined in any one of claims 1 to 8, or a physiologically acceptable salt or solvate thereof, for use in the treatment of stable, unstable and variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.

12. A compound, salt or solvate as defined in claim 9, for use in the treatment of stable, unstable and variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.

13. (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxy-phenyl)-pyrazino[2',l':6,1]pyrido[3,4-b]indole-1,4-dione, or a physiologically acceptable salt or solvate thereof, for use in the treatment of stable, unstable and variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.

14. Use of a compound of formula (I) as defined in any one of claims 1 to 8, or a physiologically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment of stable, unstable and variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.

15. Use of a compound, salt or solvate as defined in claim 9, in the manufacture of a medicament for the treatment of stable, unstable and variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.

16. Use of (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxy-phenyl)-pyrazino[2',1':6,1 ]pyrido[3,4-b]indole-1,4-dione, or a physiologically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of stable, unstable and variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, peripheral vascular disease, vascular disorders, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.

17. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 8, or a physiologically acceptable salt or solvate thereof, together with a pharmaceutically acceptable diluent or carrier therefor.

18. A pharmaceutical composition comprising a compound of claim 9, or a physiologically acceptable salt or solvate thereof, in association with a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising (6R,12aR)-2,3,6,7,12,12a-hexahydro-methyl-6(3,4-methylenedioxy-phenyl)-pyrazino[2',1':6,1 ]pyrido[3,4-b]indole-1,4-dione, or a physiologically acceptable salt or solvate thereof, in association with a pharmaceutically acceptable carrier.

20. A process of preparing a pharmaceutical composition comprising a compound according to any one of claims 1 to 10, which process comprises mixing said compound together with a pharmaceutically acceptable diluent or carrier therefor.

21. A process of preparing a compound of formula (I) as defined in claim 1, or a salt or solvate thereof, which process comprises:
a process (A) for preparing a compound of formula (I), wherein R3 represents hydrogen which process (A) comprises treating a compound of formula (II) in which Alk represents C1-6 alkyl and Hal is a halogen atom, with a primary amine R'NH2; or a process (B) for preparing a compound of formula (I), wherein R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain, which process (B) comprises cyclisation of a compound of formula (VIII) wherein Alk represents C1-6alkyl and R1 and R3 together represent a 3-or 4-membered chain both as defined above; or a process (C) for preparing a compound of formula (I) wherein R3 represents C1-3alkyl, which process (C) comprises cyclisation of a compound of formula (X) wherein Alk represents C1-6alkyl and R5 represents C2-5alkyl, substituted at C1 by a halogen atom; or process (A), (B) or (C) as hereinbefore described followed by i) an interconversion step; and/or either ii) salt formation; or iii) solvate formation.

22. A compound of formula (II) wherein:
R o represents hydrogen, halogen or C1-6 alkyl;
R1 represents hydrogen, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl;

R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3-or 4- membered alkyl or alkenyl chain, Alk represents C1-6alkyl and Hal is a halogen atom.

23. A compound of formula (III) wherein:
R o represents hydrogen, halogen or C1-6 alkyl;
R1 represents hydrogen, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl;
R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3-or 4- membered alkyl or alkenyl chain, and Alk is C1-6alkyl provided that when RO is hydrogen and R2 is phenyl, then Alk is C2-6alkyl.

24. A compound of formula (V) wherein:
RO represents hydrogen, halogen or C1-6 alkyl;
R1 represents hydrogen, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl;

R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3-or 4- membered alkyl or alkenyl chain, and Alk is C1-6alkyl provided that when RO is hydrogen and R2 is phenyl, then Alk is C2-6alkyl.

25. A compound of formula (VI) wherein:

RO represents hydrogen, halogen or C1-6 alkyl;
R1 represents hydrogen, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl;

R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or RO and R3 together represent a 3-or 4- membered alkyl or alkenyl chain, and Alk is C 1-6alkyl provided that when RO is hydrogen and R2 is phenyl, then Alk is C2-6alkyl.

26. A compound of formula (VII) wherein:
RO represents hydrogen, halogen or C1-6 alkyl;
R1 represents hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl;

R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3-or 4- membered alkyl or alkenyl chain, Hal is a halogen atom; and Alk is C1-6alkyl provided that when RO is hydrogen and R2 is phenyl, then Alk is C2-6alkyl.

27. A compound of formula (VIII) wherein:
RO represents hydrogen, halogen or C1-6 alkyl;
R1 represents hydrogen, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl;
R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3-or 4- membered alkyl or alkenyl chain, R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain;
and Alk is C1-6alkyl.

28. A compound of formula (X) wherein:

RO represents hydrogen, halogen or C1-6 alkyl;
R1 represents hydrogen, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl;
R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3-or 4- membered alkyl or alkenyl chain, Alk is C1-6alkyl and R5 is C2-5alkyl, substituted at C1 by a halogen atom.